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The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) mandates 
that the Agency for Toxic Substances and Disease Registry (ATSDR) shall assess whether adequate 
information on health effects is available for the priority hazardous substances.  Where such information 
is not available or under development, ATSDR shall, in cooperation with the National Toxicology 
Program (NTP), initiate a program of research to determine these health effects.  The Act further directs 
that where feasible, ATSDR shall develop methods to determine the health effects of substances in 
combination with other substances with which they are commonly found.  The Food Quality Protection 
Act (FQPA) of 1996 requires that factors to be considered in establishing, modifying, or revoking 
tolerances for pesticide chemical residues shall include the available information concerning the 
cumulative effects of substances that have a common mechanism of toxicity, and combined exposure 
levels to the substance and other related substances.  The FQPA requires that the Administrator of the 
Environmental Protection Agency (EPA) consult with the Secretary of the Department of Health and 
Human Services (which includes ATSDR) in implementing some of the provisions of the act. 
To carry out these legislative mandates, ATSDR’s Division of Toxicology (DT) has developed and 
coordinated a mixtures program that includes trend analysis to identify the mixtures most often found in 
environmental media, in vivo and in vitro toxicological testing of mixtures, quantitative modeling of joint 
action, and methodological development for assessment of joint toxicity.  These efforts are interrelated. 
For example, the trend analysis suggests mixtures of concern for which assessments need to be 
conducted. If data are not available, further research is recommended.  The data thus generated often 
contribute to the design, calibration or validation of the methodology.  This pragmatic approach allows 
identification of pertinent issues and their resolution as well as enhancement of our understanding of the 
mechanisms of joint toxic action.  All the information obtained is thus used to enhance existing or 
developing methods to assess the joint toxic action of environmental chemicals.  Over a number of years, 
ATSDR scientists in collaboration with mixtures risk assessors and laboratory scientists have developed 
approaches for the assessment of the joint toxic action of chemical mixtures.  As part of the mixtures 
program a series of documents, Interaction Profiles, are being developed for certain priority mixtures that 
are of special concern to ATSDR. 
The purpose of an Interaction Profile is to evaluate data on the toxicology of the “whole” priority mixture 
(if available) and on the joint toxic action of the chemicals in the mixture in order to recommend 
approaches for the exposure-based assessment of the potential hazard to public health.  Joint toxic action 
includes additivity and interactions.  A weight-of-evidence (WOE) approach is commonly used in these 
documents to evaluate the influence of interactions in the overall toxicity of the mixture.  The weight-of­
evidence evaluations are qualitative in nature, although ATSDR recognizes that observations of 
toxicological interactions depend greatly on exposure doses and that some interactions appear to have 
thresholds. Thus, the interactions are evaluated in a qualitative manner to provide a sense of what 
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Uranium and fluoride are used in conjunction with nitrate when separating isotopes of uranium via the 
gaseous diffusion process. This process has been used at several U.S. Department of Energy (DOE) 
facilities, and continues to be used today.  In addition, cyanide has been reported with great frequency as 
a contaminant at NPL sites.  Review of ATSDR’s documents with site-specific information showed that 
uranium, fluoride, cyanide, and nitrate were reported at one site (Pantax Plant site), while three-
component submixtures were reported at eight additional sites: Eastern Michaud Flats, Monticello Mill, 
Alcoa/Lavaca Bay, Depue/New Jersey Zinc/Mobil Chemical, Hipps Road Landfill, Riverbank Army 
Ammunition Plant, Savanna Army Depot, and Santa Susana Field Laboratory.  The purposes of this 
profile are to: (1) evaluate data (if available) on health hazards, and their dose-response relationships, 
from oral exposure to this four-component mixture; (2) evaluate data on the joint toxic actions of 
components of this mixture; and (3) make recommendations for exposure-based assessments of the 
potential impact of joint toxic action of the mixture on public health. 
Evaluation of the available environmental fate data for the components of the mixture suggests that in the 
event of exposure, the primary route of exposure of nearby populations to mixtures of these chemicals in 
soil is likely to be oral, resulting from contamination of soil and/or groundwater.  ATSDR toxicological 
profiles are available for cyanide, uranium, and fluoride (ATSDR 1997, 1999b, 2001d, respectively); 
these documents are the primary sources of information presented in the Appendices concerning the 
toxicokinetics, health effects, mechanisms of action, and health guidelines for these chemicals.  Neither a 
toxicological profile nor Minimal Risk Levels (MRLs) are available for nitrate; however, U.S. EPA (IRIS 
2002) has derived an oral reference dose (RfD) for nitrate. 
No studies were located that examined health effects in humans or animals exposed to mixtures 
exclusively containing uranium, fluoride, cyanide, and nitrate, and no physiologically-based 
pharmacokinetic/pharmacodynamic (PBPK/PD) models for this mixture have been developed.  A 
component-based approach (ATSDR 2001b, 2001c) was applied, wherein the potential influence of 
individual components on the toxicity of other components in the mixture is evaluated.  For the purposes 
of component analysis, the toxicity from uranium radiation was considered as a separate element from the 
chemical toxicity of uranium.  As joint action data are lacking for the majority of the component pairs, the 
mechanisms of action for each component pair were also analyzed for evidence of potential joint toxic 
actions. The weight-of-evidence analysis suggests greater-than-additive joint actions for one component 
pair (fluoride and cyanide, in both directions), and less-than-additive joint actions for two of the 
x 
component pairs (cyanide’s effect on the toxicity of uranium radiation and nitrate’s effect on cyanide 
toxicity). 
Component-based approaches that assume endpoint-specific additive joint toxic action are recommended 
for exposure-based assessments of possible noncancer or cancer health hazards from oral exposure to 
uranium, fluoride, cyanide, and nitrate, because there are no direct data available to characterize health 
hazards (and dose-response relationships) from the four-component mixture.  The weight-of-evidence 
analysis indicated that data are inadequate to characterize the modes of joint action of the majority of the 
components, but the additivity assumption appears to be suitable in the interest of protecting public 
health. 
A target-organ toxicity dose (TTD) modification of the hazard index approach is recommended for 
conducting exposure-based assessments of noncancer health hazards.  Where data are available, TTDs for 
several toxicity targets have been recommended for each of the components, including TTDs for renal, 
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The primary purpose of this Interaction Profile for uranium, fluoride, and cyanide is to evaluate data on 
the toxicology of the “whole” mixture and the joint toxic action of the chemicals in the mixture in order to 
recommend approaches for assessing the potential hazard of this mixture to public health.  To this end, 
the profile evaluates the whole mixture data (if available), focusing on the identification of health effects 
of concern, adequacy of the data as the basis for a mixture Minimal Risk Level (MRL), and adequacy and 
relevance of physiologically-based pharmacokinetic/pharmacodynamic (PBPK/PD) models for the 
mixture.  The profile also evaluates the evidence for joint toxic action—additivity and interactions— 
among the mixture components.  A weight-of-evidence (WOE) approach is commonly used in these 
profiles to evaluate the influence of interactions in the overall toxicity of the mixture.  The weight-of­
evidence evaluations are qualitative in nature, although the Agency for Toxic Substances and Disease 
Registry (ATSDR) recognizes that observations of toxicological interactions depend greatly on exposure 
doses and that some interactions appear to have thresholds.  Thus, the interactions are evaluated in a 
qualitative manner to provide a sense of what influence the interactions may have when they do occur. 
The profile provides environmental health scientists with ATSDR Division of Toxicology’s (DT) 
recommended approaches for the incorporation of the whole mixture data or the concerns for additivity 
and interactions into an assessment of the potential hazard of this mixture to public health.  These 
approaches can then be used with specific exposure data from hazardous waste sites or other exposure 
scenarios. 
Uranium and fluoride are used in conjunction with nitrate when separating isotopes of uranium via the 
gaseous diffusion process. This process has been used at 
Table 1. Data from 2001 several U.S. Department of Energy (DOE) facilities, and 
CERCLA Priority List of 
Hazardous Substances 
continues to be used today.  In addition, cyanide has been 
reported with great frequency as a contaminant at National 
Compound NPL Ranking 
Uranium 94 
Hydrogen Fluoride 248 
Fluoride 261 
Cyanide 28 
Hydrogen Cyanide 139 
Nitrate 216 
Priorities List (NPL) sites. Review of ATSDR’s documents 
with site-specific information showed that uranium, fluoride, 
cyanide, and nitrate were reported at one site (Pantax Plant 
site), while three-component submixtures were reported at eight 
additional sites: Eastern Michaud Flats, Monticello Mill, Alcoa/ 
Lavaca Bay, Depue/New Jersey Zinc/Mobil Chemical, Hipps 
Road Landfill, Riverbank Army Ammunition Plant, Savanna 
Army Depot, and Santa Susana Field Laboratory. 
2 
Data on the rankings of the individual compounds in the mixture, based on the 2001 CERCLA Priority 
List of Hazardous Substances, are presented in Table 1.  Evaluation of the available environmental fate 
data for the components of the mixture suggests that in the event of exposure, the primary route of 
exposure of nearby populations to mixtures of these chemicals in soil is likely to be oral, resulting from 
contamination of soil and/or groundwater. 
ATSDR toxicological profiles are available for cyanide, uranium, and fluoride (ATSDR 1997, 1999b, 
2001d); these documents are the primary sources of information presented in the Appendices concerning 
the toxicokinetics, health effects, mechanisms of action, and health guidelines for these chemicals.  No 
toxicological profile or MRLs are available for nitrate; however, U.S. EPA (IRIS 2002) has derived an 
oral reference dose (RfD) for nitrate. The bases for available MRLs as well as other pertinent health 
effects are presented in Table 2 and in Appendices A, B, C, and D. 
Table 2. Potential Health Effects of Concern for Intermediate and Chronic Oral Exposure 
to the Mixture Uranium, Fluoride, Cyanide, and Nitrate (see Appendices A, B, C, and D)a 
Uranium 
Uranium 
















aThe basis for the MRL is bolded and italicized; other sensitive effects are bolded; and less sensitive effects in 
common across two or more compounds are listed without bold or italics. 
3 
2. Joint Toxic Action Data for the Mixture of Concern 
and Component Mixtures 
This chapter provides a review and evaluation of the literature pertinent to joint toxic action of the 
mixture and its components.  The text is generally organized so that human data are presented first, and 
studies are grouped by route, and by endpoint where that is feasible. 
2.1 Mixture of Concern 
No studies were located that examined health effects in humans or animals exposed to mixtures 
containing uranium, fluoride, cyanide, and nitrate.  No physiologically-based pharmacokinetic (PBPK) 
models were found for mixtures of these three components. 
2.2 Component Mixtures 
The following subsections present evaluations of health effects data and discussions of mechanistic 
information pertinent to the joint toxic action of each pair of components.  For clarity, the radiologic 
effects of uranium are discussed separately from the chemical effects. 
2.2.1 Uranium and Fluoride 
Uranium and fluoride are often found in combination in the nuclear power industry, where uranium 
hexafluoride is used to enrich uranium mixtures to increase the activity.  Upon contact with moisture, 
including moisture in the air, uranium hexafluoride rapidly hydrolyzes to uranyl fluoride (UO2F2) and 
hydrogen fluoride.  As these uranium compounds see heavy industrial use, many of the studies of the 
toxicity of uranium have examined one or both of them.  It is not possible to determine the effect of the 
fluoride ions in these studies on the measured toxicity of uranium; however, similar toxic effects have 
been noted in animal studies when uranium compounds not containing fluoride were examined, providing 
strong evidence that the major effects of the studies is from the uranium ion.  None of the available 
studies of uranium and fluoride have specifically examined for the effects of fluoride; thus, the potential 
modulation of fluoride-induced toxic effects by uranium cannot be determined. 
No in vitro or in vivo studies were located regarding possible joint toxic actions between uranium and 
fluoride in affecting health-related endpoints in humans or animals.  No PBPK models for co-exposure to 






exposure to uranium and fluoride compounds is renal effects.  No other shared targets of uranium and 
fluoride were identified from the available literature. 
The most sensitive effects of chronic oral fluoride exposure are on skeletal endpoints, where fluoride 
alters the structure of the carbonate-apatite crystals, resulting in an increased bone mass, but decreased 
bone strength. Data are not available as to whether uranium could affect this incorporation and therefore 
modify the primary toxic action of fluoride. Uranium has an affiliation for bone tissue, which is a concern 
with, e.g., veterans with depleted-uranium shrapnel. Thus, the potential for interaction bears investigation. 
Uranium’s most sensitive effects are on the kidney. It is possible that renal damage might reduce the 
elimination of fluoride and thus either enhance or prolong its toxicity.  Studies have shown that urinary 
excretion of fluoride is markedly decreased in the presence of decreased renal function (ATSDR 2001d). 
Fluoride may also have effects on the kidney, with a case report noting that exposure to high levels of 
fluoride resulted in renal insufficiency and interstitial nephritis (ATSDR 2001d).  The potential 
mechanisms involved in this effect are not understood. Fluoride has also been shown to have toxic effects 
on the testes and to elicit neurological effects. As these endpoints are not sensitive endpoints for uranium 
toxicity, and no mechanistic or joint action data are available examining the effect of uranium on the 
toxicity of fluoride for these effects, a reliable projection as to the potential joint toxic action of uranium 
and fluoride cannot be made. 
The most sensitive effects of exposure to uranium compounds are renal effects, resulting in both 
functional (e.g., proteinuria, enzymuria, glucosuria) and morphologic (e.g., proximal tubule necrosis) 
changes. Uranium-induced renal changes occur primarily in the glomerulus and proximal tubule.  While 
fluoride has also been shown to elicit effects on the kidney, the mechanisms behind these effects are not 
understood. Neither is it known whether co-exposure to fluoride will alter the mechanisms of uranium 
nephrotoxicity.  Exposure to higher levels of uranium can also result in effects on other organs, including 
the liver and the thyroid.  However, the mechanisms of these effects have not been elucidated, so reliable 
projections as to the effect of co-exposure to fluoride on the mechanisms of uranium-induced hepatic and 
thyroid effects cannot be made. 
2.2.2 Uranium Radiation and Fluoride 
No in vitro or in vivo studies were located regarding possible joint toxic actions between uranium 
radiation and fluoride in affecting health-related endpoints in humans or animals.  No PBPK models for 
co-exposure to uranium radiation and fluoride were located.  While it is generally accepted that exposure 
to ionizing radiation may result in increased incidence of tumors, data on the carcinogenic effects of 
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uranium radiation are not available, and available studies of the carcinogenicity of fluoride have presented 
equivocal evidence at best, with the majority of examinations demonstrating no carcinogenic effects.  No 
additional shared targets of toxicity for uranium radiation and fluoride were located. 
The most sensitive effects of chronic oral fluoride exposure are on skeletal endpoints, where fluoride 
alters the structure of the carbonate-apatite crystals, resulting in an increased bone mass, but decreased 
bone strength. Under steady state conditions, the majority of the retained uranium in the body is in the 
kidneys and skeleton.  As such, the skeleton may also be a target of uranium radiation.  However, as alpha 
particles do not penetrate deeply into tissues, particularly hard tissues, it is not known if uranium radiation 
will influence the skeletal toxicity of fluoride.  It is feasible that damage from exposure to uranium 
radiation to cells involved in bone restructuring might result in an enhanced skeletal toxicity of fluoride, 
but no human or animal data are available to confirm this hypothesis.  Based on the pharmacokinetic 
behavior of uranium, the kidney would be expected to be exposed to the greatest share of uranium 
radiation. However, as the mechanism of renal effects of fluoride are not well understood, reliable 
projections as to the effect of uranium radiation on fluoride-induced renal toxicity cannot be made. 
Similarly, data are not available examining the potential effect of uranium radiation on other endpoints of 
fluoride toxicity, such as testicular and neurological effects, precluding estimation of the potential effects 
of uranium radiation on fluoride toxicity.  While the most sensitive target of uranium radiation is believed 
to be carcinogenesis, available studies of fluoride toxicity have demonstrated only equivocal evidence of 
carcinogenic effects at best, with other studies showing no carcinogenic effects of oral fluoride exposure. 
Exposure to ionizing radiation is known to have carcinogenic effects; as such, cancer is a potentially 
sensitive endpoint for exposure to uranium radiation.  The mechanism of this effect would be similar to 
other radionuclides, in that ionization events result in damage to cellular macromolecules and eventual 
transformation.  However, studies demonstrating carcinogenic effects from chronic exposure to uranium 
radiation are lacking, likely due to the fact that the chemical effects of uranium are generally overriding, 
even for enriched uranium.  Data are not available examining the potential effect of fluoride on the 
possible carcinogenic effects of uranium alpha radiation, and understanding of the mechanisms of fluoride 
toxicity and possible carcinogenicity are not sufficient to make reliable predictions as to the effect that co­
exposure to fluoride may have on the toxicity of uranium radiation. 
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2.2.3 Uranium and Cyanide 
No in vitro or in vivo studies were located regarding possible joint toxic actions between uranium and 
cyanide in affecting health-related endpoints in humans or animals.  No PBPK models for co-exposure to 
uranium and cyanide were located.  The primary shared targets of toxicity following oral exposure to 
uranium and cyanide compounds are endocrine (thyroid) and renal effects. 
The most sensitive effects of prolonged exposure to cyanide are effects on the testes, with developmental 
and neurological effects also being sensitive effects, and renal and thyroid effects reported at higher 
exposure levels. Cyanide is believed to cause its toxic effects by binding to iron-containing proteins, with 
a particular affinity for cytochrome c oxidase, a mitochondrial enzyme involved in oxidative metabolism. 
Binding of cyanide to this enzyme inhibits mitochondrial electron transport and results in histoxic 
hypoxia, leading to severe decrements in cellular energy availability.  No data are available examining 
potential effects of uranium on the mechanisms of cyanide toxicity. 
The most sensitive effects of exposure to uranium compounds are renal effects, resulting in both 
functional (e.g., proteinuria, enzymuria, glucosuria) and morphologic (e.g., proximal tubule necrosis) 
changes. Uranium-induced renal changes occur primarily in the glomerulus and proximal tubule.  Oral 
exposure to cyanide has also been demonstrated to result in renal toxicity, though renal endpoints are less 
sensitive targets than other cyanide-induced changes.  Data are not available that examine the potential 
effect of cyanide, and its resulting inhibition of metalloenzymes including cytochrome c oxidase, on the 
nephrotoxic effects of uranium.  Exposure to higher levels of uranium can also result in effects on the 
thyroid.  However, the mechanisms of these effects have not been elucidated, so reliable projections as to 
the effect of co-exposure to fluoride on the mechanisms of uranium-induced thyroid effects cannot be 
made. 
2.2.4 Uranium Radiation and Cyanide 
Treatment with cyanide immediately before irradiation has been shown to provide protection against the 
effects of ionizing radiation. Schubert (1991) reported that 100% of mice exposed to KCN 2 minutes 
prior to a lethal dose of gamma radiation survived, as opposed to 0% in controls.  Treatment with 
thiosulfate, which counteracts the effects of cyanide, 5 minutes prior to KCN injection resulted in 
0% survival, while treatment 3 minutes postirradiation had no effect (100% survival).  A similar 
protective effect was described in Schubert et al. (1992), who reported that mice injected with KCN 
2 minutes prior to gamma irradiation showed fewer chromosomal aberrations than irradiated control mice. 
7 
Similarly, Biaglow and Durand (1978) and Mikaelsen (1954) each reported that in vitro pretreatment with 
cyanide results in a decreased incidence of chromosomal damage in cells exposed to gamma radiation. 
The mechanism involved in cyanide-induced radioprotection has not been fully elucidated, but it is 
believed that it involves either a decreased susceptibility owing to the hypoxic state of the cells or an 
increased availability of cellular oxygen resulting from the inhibition of oxidative phosphorylation 
(Biaglow and Durand 1978; Mikaelsen 1954; Schubert 1991; Schubert et al. 1992).  However, available 
studies have demonstrated this effect only for X and gamma radiations, whereas uranium isotopes emit 
alpha particles. While the fundamental mechanisms of the various types of ionizing radiation are similar 
(ionization events leading to cellular effects), data are not available that specifically examine the effects 
of cyanide on the toxicity of alpha radiation. Furthermore, the available interaction studies are of acute 
duration. It is unknown whether cyanide would offer protection on a more chronic basis. 
No in vitro or in vivo studies were located regarding possible joint toxic actions between uranium 
radiation and cyanide in affecting health-related endpoints in humans or animals.  No PBPK models for 
co-exposure to uranium radiation and cyanide were located.  While radiation is believed to result in 
increased incidence of tumors, chronic studies of the effects of cyanide are inadequate to assess the 
potential carcinogenicity of cyanide.  No additional shared targets of toxicity for uranium radiation and 
cyanide were identified by the available literature. 
2.2.5 Uranium and Nitrate 
No in vitro or in vivo studies were located regarding possible joint toxic actions between uranium and 
nitrate in affecting health-related endpoints in humans or animals.  While the literature contains reports of 
studies examining the effects of uranium nitrate, they have focused exclusively on the effects of the 
uranium ion.  No PBPK models for co-exposure to uranium and nitrate were located.  From the available 
data, uranium and nitrate do not appear to have any sensitive shared targets of toxicity.  Similarly, the 
present understanding of the mechanisms of action of these compounds does not suggest any potential 
joint actions of uranium and nitrate. 
2.2.6 Uranium Radiation and Nitrate 
No in vitro or in vivo studies were located regarding possible joint toxic actions between uranium 
radiation and nitrate in affecting health-related endpoints in humans or animals.  No PBPK models for co­
exposure to uranium radiation and nitrate were located.  From the available data, uranium radiation and 
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nitrate do not appear to have any sensitive shared targets of toxicity.  Similarly, our understanding of the 
mechanisms of action of these compounds does not suggest any potential joint actions of uranium 
radiation and nitrate. 
2.2.7 Fluoride and Cyanide 
Both fluoride and cyanide ions have been demonstrated to affect cellular energy metabolism, with 
fluoride primarily resulting in decreased glycosolation reactions, while cyanide is an inhibitor of 
oxidative phosphorylation.  Szabo et al. (1973) demonstrated that fluoride and cyanide have opposite 
effects on cellular glucose metabolism, with fluoride treatment resulting in a decrease in cellular glucose 
uptake in cultured cells, while cyanide treatment resulted in increased uptake; the increased glucose 
uptake resulting from cyanide exposure is thought to represent an increased use of the glycolytic 
pathways subsequent to inhibition of oxidative metabolism.  Co-exposure of the cells to the same 
concentrations of both fluoride and cyanide resulted in decreased glucose uptake, but not to the same 
extent as fluoride alone. However, no in vivo studies in humans or animals that examined possible joint 
toxic actions of fluoride and cyanide in affecting health-related endpoints in humans or animals were 
located. No PBPK models for co-exposure to fluoride and cyanide were located. 
Shared targets of toxicity of fluoride and cyanide include reproductive (testicular), neurological, and renal 
effects. The intermediate oral MRL for cyanide is based on decreased testicular weight and altered 
spermatogenesis in F344 rats exposed for 13 weeks in drinking water (NTP 1993).  Fluoride has also been 
shown to elicit effects on the testes, though only at doses approximately 10-fold greater than the most 
sensitive effects for fluoride. Similarly, high-dose exposure to either fluoride or cyanide can result in 
neurological and renal changes. Cyanide does not appear to have an effect on skeletal endpoints, which 
are the critical effect for the chronic MRL for fluoride.  As cyanide has a negative effect on oxidative 
metabolism and fluoride has been shown to reduce glycolysis (Szabo et al. 1973), it is possible that joint 
effects on cellular energy status may result in nonadditive effects of fluoride and cyanide.  However, the 
available data are sufficient neither to predict the direction or extent of this potential interaction nor the 
organ or organs in which it may potentially occur. 
2.2.8 Fluoride and Nitrate 
No in vitro or in vivo studies were located regarding possible joint toxic actions between fluoride and 
nitrate in affecting health-related endpoints in humans or animals.  No PBPK models for co-exposure to 
fluoride and nitrate were located. From the available data, fluoride and nitrate do not appear to have any 
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sensitive shared targets of toxicity.  Similarly, understanding of the mechanisms of action of these 
compounds does not suggest any potential joint actions of fluoride and nitrate.  A study by Whitford and 
Pashley (1991) demonstrated that renal acidification resulting from an injection of sodium nitrite would 
increase the renal reabsorption of fluoride ions in dogs; however, the potential influence of this on the 
toxicity of fluoride has not been established. 
2.2.9 Cyanide and Nitrate 
No studies directly examining the toxic effects of simultaneous oral exposure to cyanide and nitrate were 
located in the literature. However, as described in Appendix D, approximately 5–10% of an oral dose of 
nitrate will be converted to nitrite by gastrointestinal bacteria.  Nitrate has long been administered, alone 
or in combination, as an antidote against the acute lethal effects of cyanide; in recent years, a combination 
of nitrite and sodium thiosulfide has been used.  Increased levels of methemoglobin, resulting from nitrite 
exposure, compete with cytochrome c oxidase for cyanide ions, forming cyanmethemoglobin and thereby 
reducing the lethality of cyanide, usually on the order of a 3- to 5-fold reduction.  For example, Burrows 
and Way (1979) reported that injection of 22 mg/kg sodium nitrite 5 minutes after a single oral dose of 
sodium cyanide in sheep resulted in an increase in the 50% lethal dose (LD50) from 3.7 to 14.1 mg/kg, but 
no change in the slope of the dose-response curve. Similarly, Cannon et al. (1994) reported that in mice, 
the LD50 values for a subcutaneous injection of potassium cyanide with and without pretreatment with an 
injection of 100 mg/kg sodium nitrite were 10.1 and 28.6 mg/kg, respectively, while Chen and Rose 
(1952) reported a 5-fold increase in the LD50 of subcutaneous sodium cyanide in dogs given intravenous 
sodium nitrite. 
The traditionally proposed mechanism of nitrite-induced protection against cyanide toxicity has been 
well-established. For example, Tadic (1992) reported that injection of sodium nitrite 30 minutes after 
subcutaneous injection of 20 mg/kg sodium cyanide resulted in a restoration of brain cytochrome oxidase 
activity, while Isom and Way (1974) reported that subcutaneous injection of 100 mg/kg sodium nitrite 
reduced the increase in glycolysis normally seen with cyanide intoxication.  More recent examinations 
have discovered other potential mechanisms that are believed to come into play with combination 
treatments of sodium nitrite and other compounds (Paitian et al. 1985; Way et al. 1988).  However, these 
mechanisms may also be the result of co-administration of nitrite and the other compounds, rather than 
from nitrite itself.  The potential contribution of these mechanisms to nitrite’s reduction of cyanide 
toxicity is not known, though they are believed to result in more efficient detoxification.  Additional 
characterizations of non-methemoglobin mechanisms of nitrite-induced protection against cyanide 
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toxicity will be required in order to adequately assess the potential role they may play in the joint toxic 
actions of nitrate and cyanide. 
Data are not available examining the potential effects of cyanide on the toxicity of nitrate, and 
mechanistic understanding is not sufficient to predict the direction and/or magnitude of any potential 
effect of cyanide exposure on nitrate toxicity.  No PBPK models for co-exposure to cyanide and nitrate 
were located. Cyanide and nitrate do not appear to have any sensitive shared targets of toxicity. 
2.3 Relevance of the Joint Toxic Action Data and Approaches to Public Health 
Mixtures containing uranium, fluoride, cyanide, and nitrate may be found together at hazardous waste 
sites, most notably those located at present or former DOE facilities.  No studies examining a complete 
mixture of these compounds were located in the literature.  No PBPK models are available for the 
complete mixture, or for any of the two- or three-component submixtures. 
In the absence of studies that examine relevant endpoints and describe dose-response relationships 
following oral exposures to mixtures that contain these chemicals (e.g., in food or in soil), component-
based approaches to assessing their joint action that assume dose additivity for noncancer effects appear 
to be reasonable for practical public health concerns.  Carcinogenic effects are believed to be a sensitive 
health effect only for uranium radiation, and even in that case, data demonstrating carcinogenic effects of 
uranium radiation following oral exposure are not available.  Therefore, an approach focusing on the 
carcinogenic risks of that component as being of greatest concern for the mixture seems to be reasonable. 
In the introduction to this document, Table 2 presented an overview of the potential health effects of 
concern from oral exposure to uranium, uranium radiation, fluoride, cyanide, and nitrate.  Each of the four 
compounds affects a variety of target organs and endpoints.  There are few target organs in common 
across two or more of the components of the mixture.  In the cases where an endpoint is shared, it is 
generally a sensitive target of one compound, but a high-dose effect of the other.  The exception to this is 
the shared target of testicular effects of fluoride and cyanide.  As shown in Table 3, however, the oral 
MRLs for uranium, fluoride, and cyanide are based on different endpoints, and oral MRLs have not been 
derived for uranium radiation and nitrates.  Available data on possible binary interactions among these 
four chemicals are limited for most of the pairs.  PBPK models that predict the disposition of these 
chemicals are not available for the complete mixture, for ternary submixtures, or for any of the binary 
component pairs of the mixture.  Tables 4 through 7 describe binary weight-of-evidence (BINWOE) 
evaluations for the pairs of the chemicals of concern using the classification scheme summarized in 
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Table 3. Health Effects Forming the Basis of ATSDR Oral MRLs for Chemicals of Concern 
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None derived, no 
Toxicological 
Profile 







effects in rats 
None derived, no 
Toxicological 
Profile 




Increased risk of 





None derived, no 
Toxicological 
Profile 
Figure 1 and in ATSDR (2001b). The selection of target organs or endpoints for BINWOE development 
takes into account the critical effects of the individual components.  In addition, and particularly if the 
components do not have the same critical effect, the selection also takes into account other relatively 
sensitive effects in common across two or more components of the mixture.  The conclusions in these 
tables were based on the evaluations of the pertinent literature presented in Section 2.2.  The BINWOEs 
focus on repeated simultaneous oral exposure, since this is the exposure scenario of most interest for 
public health concerns for the subject chemicals and their mixture.  A summary discussion of the 
BINWOEs follows this paragraph and precedes the descriptive tables. 
There are no pertinent interaction data, and understanding of mechanisms of action is too incomplete to 
make projections of joint toxic actions between the following pairs of chemicals: 
C Uranium and fluoride;
 
C Uranium and cyanide;
 
C Uranium and nitrate;
 
C Uranium radiation and fluoride;
 
C Uranium radiation and nitrate; and
 




Evidence of varying quality and quantity is available supporting projections of joint toxic action for the 
following pairs of chemicals: 
C Uranium radiation and cyanide (Tables 4 and 5);
 
C Fluoride and cyanide (Tables 6 and 7); and
 
C Cyanide and nitrate (Tables 8 and 9)
 
For uranium radiation and cyanide and cyanide and nitrate, data are available in only one direction.  For 
example, data are available on the effect of cyanide on the toxicity of uranium radiation, but not for the 
effect of uranium radiation on the toxicity of cyanide.  While data suggesting joint actions of fluoride and 
cyanide are limited, they suggest that the effects will occur in both directions. 
In summary, there are no data that suggest that non-additive interactions occur for the majority of the 
component pairs, though it should be emphasized that studies designed to identify and characterize mode 
of joint toxic action of the components are, for the most part, unavailable.  In two cases, the effect of 
cyanide on the toxicity of uranium radiation and the effect of nitrite on the toxicity of cyanide, the 
available data suggest less-than-additive joint action of the component pairs, and in one case, the joint 
action of fluoride and cyanide, the available data suggest a greater-than-additive joint action for the 
component pair. 
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Figure 1. Binary Weight-of-Evidence Scheme for the Assessment of Chemical Interactions* 
Classification Factor 
Direction of Interaction Direction 
= Additive 0 
> Greater than additive +1 
< Less than additive -1
? Indeterminate  0 
Quality of the Data	 Weighting 
Mechanistic Understanding 
I.	 Direct and Unambiguous Mechanistic Data: The mechanism(s) by which the 1.0 
interactions could occur has been well characterized and leads to an 
unambiguous interpretation of the direction of the interaction. 
II.	 Mechanistic Data on Related Compounds: The mechanism(s) by which the 0.71 
interactions could occur has not been well characterized for the chemicals of 
concern but structure-activity relationships, either quantitative or informal, can 
be used to infer the likely mechanism(s) and the direction of the interaction. 
III.	 Inadequate or Ambiguous Mechanistic Data: The mechanism(s) by which the 0.32 
interactions could occur has not been well characterized or information on the 
mechanism(s) does not clearly indicate the direction that the interaction will 
have. 
Toxicological Significance 
A.	 The toxicological significance of the interaction has been directly demonstrated. 1.0 
B.	 The toxicological significance of the interaction can be inferred or has been 0.71 
demonstrated for related chemicals. 
C.	 The toxicological significance of the interaction is unclear. 0.32 
Modifiers 
1.	 Anticipated exposure duration and sequence. 1.0 
2.	 Different exposure duration or sequence. 0.79 
a.	 In vivo data 1.0 
b.	 In vitro data 0.79 
i.	 Anticipated route of exposure 1.0 
ii.	 Different route of exposure 0.79 
Weighting Factor = Product of Weighting Scores: Maximum = 1.0, Minimum = 0.05
 
BINWOE = Direction Factor x Weighting Factor:  Ranges from !1 through 0 to +1
 
*Source: ATSDR 2001b, 2001c 
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Table 4. Effect of Uranium Radiation on Cyanide 
BINWOE: ? (0) 
Direction of Interaction - The direction of the interaction cannot be predicted in the absence of 
(1) pertinent interaction data; (2) information clearly indicating that pharmacokinetic interactions with 
uranium radiation will influence the toxicity of cyanide; or (3) mechanistic understanding leading to an 
unambiguous projection of interactions between uranium radiation and cyanide. 
Mechanistic Understanding - The most sensitive effects of cyanide are effects on the testes, with 
developmental and neurological effects also being sensitive effects, and renal and thyroid effects 
reported at higher exposure levels. Cyanide is believed to cause its toxic effects by binding to iron-
containing proteins, with a particular affinity for cytochrome c oxidase, a mitochondrial enzyme 
involved in oxidative metabolism.  Binding of cyanide to this enzyme inhibits mitochondrial electron 
transport and results in histoxic hypoxia, leading to severe decrements in cellular energy availability. 
No data are available examining potential effects of uranium radiation on the mechanisms of cyanide 
toxicity. 
Toxicological Significance - Relevant interaction data on pertinent health effects with simultaneous 
oral exposure were not located. No studies were located in which treatment with uranium radiation 
before cyanide exposure was examined. 





Table 5. Effect of Cyanide on Uranium Radiation 
BINWOE: <IIB2ii (-1 x 0.71 x 0.71 x 0.79 x 0.79 = -0.31) 
for carcinogenic effects 
Direction of Interaction - Several studies have established that treatment with cyanide immediately 
prior to an exposure to ionizing radiation results in decreased toxicity (lethality, chromosomal damage) 
of the radiation exposure (Biaglow and Durand 1978; Mikaelsen 1954; Schubert 1991; Schubert et al. 
1992). The proposed direction of interaction is therefore less than additive. 
Mechanistic Understanding - The mechanism by which cyanide reduces the susceptibility to ionizing 
radiation is not fully understood.  Cyanide must be actively inhibiting cytochrome c oxidase to be 
radioprotective, as demonstrated by Schubert (1991), who reported that injection of mice with KCN 
2 minutes prior to irradiation with an otherwise 100% lethal dose of gamma radiation resulted in 
complete protection (100% survival), unless thiosulfate, a cyanide antagonist, was given 5 minutes 
prior to irradiation, in which case survival was 0%.  While these studies were performed using isotopes 
that were not alpha emitters, the mechanism of action for alpha and gamma radiations (ionization 
events leading to cellular damage) is expected to be similar.  Therefore, the mechanisms resulting in a 
protective effect of cyanide against gamma and X-irradiation are expected to function against 
ionizations caused by alpha radiation, such as is emitted by uranium isotopes.  However, because of the 
different average path lengths of the radiations, the distribution of the emissions from uranium will 
likely be quite different from a whole-body gamma radiation exposure.  A confidence rating of “II” 
was therefore assigned for mechanistic understanding, reflecting mechanistic data from related 
compounds. 
Toxicological Significance - Relevant interaction data on pertinent health effects with simultaneous 
oral exposure were not located. The studies of Schubert (1991) and Schubert et al. (1992) examined 
toxicologically relevant endpoints, specifically lethality and chromosomal aberrations, following 
pretreatment with cyanide prior to gamma irradiation, but no studies examining pretreatment with 
cyanide prior to exposure to uranium radiation were located.  Both Biaglow and Durand (1978) and 
Mikaelsen (1954) reported that in vitro pretreatment with cyanide results in a decreased incidence of 
chromosomal damage in cells exposed to gamma radiation; no in vitro studies examining the effect of 
pretreatment with cyanide on the effects of uranium radiation were located. All interaction studies were 
of acute duration; it is unknown whether cyanide would offer protection on a more chronic basis. A 
confidence rating of “B” was assigned for toxicological significance. 
Modifying Factors - Available studies of the radioprotective effects of cyanide have been conducted 
using acute injection exposures. Therefore, modifying factors of 0.79 for different exposure duration/ 
sequence (2) and 0.79 for different exposure route (ii) were applied to the BINWOE. 
Additional Uncertainties - The rating of II (and the corresponding 0.71 weighting factor) for 
mechanistic understanding and the modifying factor of 0.79 for different exposure route do not fully 
express the uncertainties associated with the applicability of extrapolation of data on the effects of 
gamma radiation to the effects of alpha radiation. 
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Table 6. Effect of Fluoride on Cyanide 
BINWOE: >IIIC2b (1 x 0.32 x 0.32 x 0.79 x 0.79 = 0.06) 
Direction of Interaction - The direction of action for the effects of fluoride on the toxicity of cyanide is 
expected to be greater than additive based on mechanistic studies of fluoride and cyanide. 
Mechanistic Understanding - Both fluoride and cyanide ions have been demonstrated to affect cellular 
energy metabolism, with fluoride primarily resulting in decreased glycosolation reactions, while 
cyanide is an inhibitor of oxidative phosphorylation.  These two appear to act independently on 
different sites of energy metabolism.  Szabo et al. (1973) demonstrated that fluoride and cyanide have 
opposite effects on cellular glucose uptake, with fluoride treatment resulting in a decrease in cellular 
glucose uptake in cultured cells, while cyanide treatment resulted in increased uptake; the increased 
glucose uptake resulting from cyanide exposure is thought to represent an increased use of the 
glycolytic pathways subsequent to inhibition of oxidative metabolism.  Co-exposure of the cells to the 
same concentrations of both fluoride and cyanide resulted in decreased glucose uptake, but not to the 
same extent as fluoride alone.  However, no studies directly examining the effect of fluoride on the 
toxicity of cyanide were located.  A rating of “III” was therefore applied for mechanistic 
understanding. 
Toxicological Significance - No in vivo studies of the joint action of fluoride and cyanide were located 
in the literature. The only study that examined the joint action of fluoride and cyanide examined a 
metabolic endpoint, rather than a known toxic effect of cyanide.  A rating of “C” was therefore selected 
for toxicological significance. 
Modifying Factors - Available data on joint action are limited to single-exposure in vitro studies. As 
such, modifying factors for different exposure duration (2) and in vitro data (b) were applied. 
Additional Uncertainties - Uncertainties have been addressed in the above discussion. 
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Table 7. Effect of Cyanide on Fluoride 
BINWOE: >IIIC2b (1 x 0.32 x 0.32 x 0.79 x 0.79 = 0.06) 
Direction of Interaction - The direction of action for the effects of cyanide on the toxicity of fluoride is 
expected to be greater than additive based on mechanistic studies of cyanide and fluoride. 
Mechanistic Understanding - Both cyanide and fluoride ions have been demonstrated to affect cellular 
energy metabolism, with fluoride primarily resulting in decreased glycosolation reactions, while 
cyanide is an inhibitor of oxidative phosphorylation.  These two appear to act independently on 
different sites of energy metabolism.  Szabo et al. (1973) demonstrated that fluoride and cyanide have 
opposite effects on cellular glucose metabolism, with fluoride treatment resulting in a decrease in 
cellular glucose uptake in cultured cells, while cyanide treatment resulted in increased uptake; the 
increased glucose uptake resulting from cyanide exposure is thought to represent an increased use of 
the glycolytic pathways subsequent to inhibition of oxidative metabolism.  Co-exposure of the cells to 
the same concentrations of both fluoride and cyanide resulted in decreased glucose uptake, but not to 
the same extent as fluoride alone.  However, no studies directly examining the effect of cyanide on the 
toxicity of fluoride were located.  A rating of “III” was therefore applied for mechanistic 
understanding. 
Toxicological Significance - No in vivo studies of the joint toxic action of cyanide and fluoride were 
located in the literature. The only study that examined the joint action of cyanide and fluoride 
examined a metabolic endpoint, which was a known toxic effect of fluoride.  A rating of “C” was 
therefore selected for toxicological significance. 
Modifying Factors - Available data on joint action of cyanide and fluoride are limited to single-
exposure in vitro studies. As such, modifying factors for different exposure duration (2) and in vitro 
data (b) were applied. 
Additional Uncertainties - Uncertainties have been addressed in the above discussion. 
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Table 8. Effect of Cyanide on Nitrate 
BINWOE: ? (0) 
Direction of Interaction - The direction of the interaction cannot be predicted in the absence of 
(1) pertinent interaction data; (2) information clearly indicating that pharmacokinetic interactions with 
cyanide will influence the toxicity of nitrate; or (3) mechanistic understanding leading to an 
unambiguous projection of interactions between cyanide and nitrate. 
Mechanistic Understanding - Both cyanide and nitrate exert their main effects through fairly well-
characterized mechanisms of action.  It is believed that the bulk of the known effects of cyanide result 
from its interaction with the iron atom of cytochrome c oxidase.  The only known effects of nitrate 
result from its metabolism to nitrite and resulting methemoglobinemia.  While it is believed that the 
actions of nitrate may decrease the toxicity of cyanide (see Table 9 below), our understanding of the 
mechanisms and effects of nitrate-induced methemoglobinemia does not allow for accurate predictions 
as to whether or not co-exposure to cyanide will influence the toxicity of nitrate. 
Toxicological Significance - Relevant interaction data on pertinent health effects with simultaneous 
oral exposure were not located. No studies were located in which treatment with cyanide before nitrate 
exposure was examined. 
Additional Uncertainties - Uncertainties have been addressed in the above discussion. 
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Table 9. Effect of Nitrate on Cyanide 




BINWOE: <IIB2ii (-1 x 0.71 x 0.71 x 0.79 x 0.79 = -0.31)
 
for all other effects of cyanide
 
Direction of Interaction - The direction of action for the effects of nitrate on the toxicity of cyanide is 
expected to be less than additive, based on mechanistic studies of nitrate metabolism and numerous 
studies of the use of nitrite-containing compounds as antidotes to acute cyanide toxicity. 
Mechanistic Understanding - As discussed in Appendix D, a small percentage, perhaps 5–10%, of an 
oral nitrate dose is converted to nitrite by bacteria of the gastrointestinal tract.  Nitrite-induced 
formation of methemoglobin, either alone or in combination with other agents, has been used for many 
years as an antidote to acute cyanide toxicity in humans.  Methemoglobin competes with cytochrome 
c oxidase for cyanide, resulting in diminished inhibition of respiratory function as a result of cyanide 
exposure. Re-establishment of brain levels of cytochrome oxidase enzyme levels has been 
demonstrated in acute in vivo studies (Isom and Way 1974; Tadic 1992); the mechanistic 
understanding for neurologic effects of cyanide was therefore given a rating of “I”.  The effect of 
nitrate (or nitrite) on other potential effects of cyanide has not been directly examined.  However, the 
mechanism discussed above (methemoglobin competition for binding of cyanide ions) is likely to be 
applicable to these other endpoints as well. They were therefore assigned a confidence rating of “II” 
for mechanistic understanding.  While more recent studies have suggested that nitrite may protect 
against cyanide toxicity by other mechanisms as well, these mechanisms are not presently well-
elucidated. 
Toxicological Significance - Relevant interaction data on pertinent health effects with simultaneous 
oral exposure were not located. No studies were located in which treatment with nitrate before or after 
cyanide exposure was examined.  As discussed above, a metabolite of nitrate, nitrite, has been shown 
to be protective against the neurologic effects of acute cyanide toxicity.  A rating of “A” was therefore 
assigned for toxicological significance for neurological effects, and a rating of “B” was assigned for 
toxicological significance for other effects of cyanide. 
Modifying Factors - Available studies of nitrite-induced protection against cyanide toxicity have been 
mainly of acute duration and intravenous exposure.  Thus, modifiers of 0.79 for different exposure 
duration/sequence (2) and 0.79 for different exposure route (ii) were applied. 
Additional Uncertainties - Uncertainties have been addressed in the above discussion. 
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2.4 Recommendations for Data Needs 
Neither in vivo data from human or animal studies nor in vitro data examining the toxicity of the four-
component mixture, or for three-component submixtures, are available.  Similarly, PBPK models 
describing the behavior of the four-component mixture or the three-component submixtures are not 
available. In the absence of data for the complete mixture, a component-based approach was utilized. 
However, data on the joint toxic action of the component pairs of the mixture are lacking, with no 
adequate joint action data available for any of the nine component pairs of the mixture.  Data on the 
potential mechanistic interactions between the component pairs are also lacking for the majority of the 
component pairs, with only the effect of nitrate on cyanide having a solid mechanistic basis for 
determination of potential joint action.  Data are also available on the effect of cyanide on uranium 
radiation, but the data are limited to studies of related compounds, specifically other types of radiation. 
Fluoride and cyanide affect separate targets involved in energy metabolism, but studies of their joint 
toxicity are not available. 
For the individual components, chronic oral MRLs are available for uranium (the intermediate MRL is 
believed to be protective for chronic exposure) and fluoride.  An intermediate oral MRL is available for 
cyanide, and MRLs are not available for exposure to uranium radiation or to nitrate for any duration.  The 
U.S. Environmental Protection Agency (EPA) (IRIS 2002) has derived a RfD for nitrate, based on 
methemoglobinemia; in practice, health assessments may use this RfD until such time as a chronic oral 
MRL for nitrate is derived. Additional data are needed if MRLs are to be derived for uranium radiation. 
Studies furthering our understanding of the mechanisms of the toxicity of the individual components, and 
component pairs, may also aid in understanding of the potential modes of joint action of the component 
pairs of the mixture. 
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3. Recommendation for Exposure-Based Assessment of 
Joint Toxic Action of the Mixture 
Examination of the available joint toxic action data, presented in Section 2.2, reveals that no health effects 
data are available for the complete mixture, or for ternary submixtures.  Because suitable toxicity data, 
joint action models, and PBPK models are lacking for the complete mixture, the recommended approach 
for the exposure-based assessment of joint toxic action of this mixture is to use a hazard index approach 
with a target-organ toxicity dose (TTD) modification and a qualitative WOE method.  The hazard index, 
together with the WOE approach, assesses the potential consequences of additive and interactive joint 
action of the components of the mixture on noncarcinogenic endpoints of concern (ATSDR 2001b). 
Table 10 presents a matrix of the BINWOE values, where available, for each of the component pairs of 
the chemicals of concern as discussed in Chapter 2. Where appropriate, TTDs for oral exposure scenarios 
have been derived as described in the Appendices, using the methods recommended by ATSDR (2001b). 
However, in some cases, particularly for fluoride and cyanide, the effects on less-sensitive endpoints are 
not well studied, resulting in the application of very high uncertainty factors in calculation of TTD values. 
When the uncertainty associated with TTD calculation would result in numerical values lower than those 
of the MRL, which is based on the most sensitive observed effect identified and which is, in most cases, 
much better studied, the MRL value was recommended instead.  Table 11 lists numerical values of these 
TTDs, and of the MRLs where available, for the shared endpoints of concern for chronic oral exposure to 
this mixture: renal, reproductive, and neurological effects.  Additionally, for two components, fluoride 
and nitrate, the most sensitive endpoint is not a shared target of toxicity for the mixture.  Therefore, the 
chronic MRL for fluoride is also presented. Since no toxicological profile or MRLs exist for nitrate, the 
RfD derived by U.S. EPA (IRIS 2002), is presented.  Hazard indices for these unique sensitive endpoints 
can be calculated based on the MRL or RfD, respectively. 
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Table 10. Matrix of BINWOE Determinations for Neurological, Developmental, Reproductive,
 
Renal, and Carcinogenic Effects of Intermediate or Chronic Simultaneous 

Oral Exposure to Chemicals of Concern
 
ON TOXICITY OF 
Uranium 
Uranium 





Uranium ? (0) ? (0) ? (0) 
Uranium 
Radiation 
? (0) ? (0) ? (0) 
C Fluoride ? (0) ? (0) >IIIC2b (0.06) ? (0) 
T 
Cyanide ? (0) <IIB2ii (-0.31) c >IIIC2b (0.06) ? (0) 
O 
F Nitrate ? (0) ? (0) ? (0) <IA2ii n (-0.62) 
<IIB2ii r, d, k (-0.31) 
c = cancer; d = developmental; k = renal (kidney); n = neurological; r = reproductive 
The BINWOE determinations were explained in Section 2.3.  No pertinent interactions data were 
available for the pairs of metals classified as indeterminate (?), and mechanistic information appeared 
inadequate or ambiguous, so indeterminate ratings were assigned to these pairs. 
BINWOE scheme (with numerical weights in parentheses) condensed from ATSDR (2001b, 2001c). 
Direction: = additive (0); > greater than additive (+1): < less than additive (–1); ? indeterminate (0) 
Mechanistic Understanding 
I.	 Direct and unambiguous mechanistic data to support direction of interaction (1.0). 
II.	 Mechanistic data on related compounds to infer mechanism(s) and likely direction (0.71). 
III.	 Inadequate and ambiguous mechanistic data do not clearly indicate direction of interaction (0.32). 
Toxicological Significance 
A.	 The toxicological significance of the interaction has been directly demonstrated (1.0). 
B.	 The toxicologic significance of interaction is inferred or has been demonstrated for related 
chemicals (0.71). 
C.	 The toxicologic significance of interaction is unclear (0.32). 
Modifiers 
1.	 Anticipated exposure duration and sequence (1.0). 
2.	 Different exposure duration or sequence (0.79). 
a.	 In vivo data (1.0) 
b.	 In vitro data (0.79) 
i.	 Anticipated route of exposure (1.0) 
ii.	 Different route of exposure (0.79) 
  
23 
Table 11. Target Organ Toxicity Doses (TTDs) and MRLs for Chronic Oral Exposure to 









ID 0.06 mg/kg/day 0.05 mg/kg/day NA 
Reproductive 





Neurological NA ID 0.06 mg/kg/day 0.05 mg/kg/day NA 





Hematological NA ID NA NA 1.6 mg/kg/day (EPA RfD) 
ID = Inadequate data to derive a TTD for the selected endpoint; NA = Selected endpoint does not appear to be a 
sensitive target, or data are not available 
Proceeding with the TTD modification of the hazard index approach involves calculating endpoint-
specific hazard indices for each endpoint of concern, as described in ATSDR (2001c, Section 2.3.2 and 
Figure 2 with accompanying text).  For example, a hazard index for renal effects of this mixture is 
calculated as follows: 
where HIRENAL is the hazard index for renal toxicity, EU is the exposure to uranium (as the oral intake in 
the same units as the corresponding MRL, in this case mg/kg/day, calculated as described above), EF is 
the exposure to fluoride (as the oral intake in the same units as the corresponding TDD, mg/kg/day), 
MRLU RENAL is the MRL for the renal toxicity of uranium, and so forth.  Components for which data are not 
available, and therefore no TTD can be derived, are not included in the endpoint-specific hazard index 
calculation. 
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Because the available evidence supports the existence of one or more non-additive joint toxic actions, 
consideration must be given as to the effect of these actions on evaluations of the toxicity of the entire 
mixture.  A less-than-additive effect of nitrate on the toxicity of cyanide was reported in the BINWOEs, 
based on high-dose acute data on nitrite injection in humans in combination with the observation that 
small amounts of oral nitrate are metabolized to nitrite.  However, a recommendation of the assumption of 
additive joint action for the nitrate and cyanide is still considered appropriate, due to (1) the uncertainty 
associated with application of data from acute injection studies to chronic, low-level oral exposures; (2) a 
lack of data supporting the assumption that significant amounts of nitrate will be converted to nitrate at 
very low exposure levels; and (3) a lack of data supporting the assumption that the mechanism of the 
acute toxicity of cyanide, which is ameliorated by nitrite-induced methemoglobinemia, is an important 
mechanism in determining the intermediate and chronic effects of cyanide.  Given these uncertainties, and 
the relatively small proportion of nitrate that is converted to nitrite, a protective effect of nitrate on 
cyanide toxicity is expected only at very high nitrate exposure levels, where significant nitrite formation 
would be seen. Therefore, for chronic, low-level exposure, the assumption of additivity is recommended. 
Examination of the weight of evidence also indicates the possibility of greater-than-additive action for the 
toxicity of fluoride and cyanide, based on their potential joint effects on energy metabolism.  However, 
data examining this potential for joint action are extremely limited, with only a single acute in vitro study 
examining glucose uptake to support the mechanism.  As such, while the available data are suggestive of 
a greater-than-additive joint action of fluoride and cyanide, additional joint action data will be necessary 
before the effect of this potential mechanism on the toxicity of the mixture can be adequately evaluated. 
In the absence of an adequate evaluation, the default assumption of additivity is recommended. 
These methods are to be applied only under circumstances involving significant exposure to the mixture, 
i.e., only if hazard quotients for two or more of the compounds equal or exceed 0.1 (Figure 2 of ATSDR 
2001c). Hazard quotients are the ratios of exposure estimates to noncancer health guideline values, such 
as MRLs. If only one or if none of the compounds have a hazard quotient that equals or exceeds 0.1, then 
no further assessment of the joint toxic action is needed because additivity and/or interactions are unlikely 
to result in significant health hazard. If one or more of the endpoint-specific hazard indices exceed 1, 
they provide preliminary evidence that the mixture may constitute a health hazard due to the joint toxic 
action of the components on that endpoint.  As discussed by ATSDR (1992, 2001c), the exposure-based 
assessment of potential health hazard is used in conjunction with biomedical judgment, community-
specific health outcome data, and community health concerns to assess the degree of public health hazard. 
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The default approach for a multi-component mixture for which no data on the carcinogenicity of the 
mixture are available and no PBPK models have been validated would involve calculating the 
carcinogenic risk for each component by multiplying lifetime oral exposure estimates for each component 
by the appropriate EPA cancer oral slope factor (an estimate of cancer risk per unit of exposure).  If only 
one or if none of the component risks equals or exceeds 1x10-6, then no further assessment of joint toxic 
action would be needed due to the low likelihood that additivity and/or interactions would result in a 
significant health hazard. However, in the case of the present mixture, only exposure to radiation from 
uranium is presently believed to result in carcinogenic effects.  As such, when assessing the carcinogenic 
risks of the mixture uranium, fluoride, cyanide, and nitrate, focus should be placed primarily on the risk 
of carcinogenic effects of uranium radiation.  While there is a suggestion that co-exposure to cyanide may 
result in a reduction of the carcinogenic effects of uranium radiation, as evidenced by a less-than-additive 
BINWOE, neither the data on uranium radiation-induced carcinogenesis nor the data supporting a less­
than-additive effect of cyanide upon those carcinogenic effects are presently sufficient to warrant an 
alteration of the default approach. A health-protective approach that does not assume a reduction of 





There are no direct data available to characterize health hazards (and dose-response relationships) from 
mixtures containing all four of the components.  Similarly, PBPK/PD models have not yet been 
developed that would predict pertinent target tissue doses of the components under scenarios involving 
exposure to mixtures of all four components.  Finally, available information on toxic actions of the 
individual components indicates that joint actions of uranium, fluoride, cyanide, and nitrate on three 
toxicity targets are plausible, specifically: reproductive effects, neurologic alterations, and renal effects. 
For two of the components, fluoride and nitrate, the most sensitive health effect does not appear to be a 
shared target with other components, but should be considered when evaluating sites containing the 
potential health hazards resulting from exposure to the mixture.  With data on the individual components 
suggesting possible sites of joint toxic action, but no data available on the toxicity or behavior of the 
complete mixture or the relevant submixtures, a default component-based approach that assumes additive 
joint toxic action in exposure-based assessments of possible noncancer health hazards from oral exposure 
to mixtures of uranium, fluoride, cyanide, and nitrate was recommended. 
Weight-of-evidence analyses of available data on the joint toxic action of mixtures of these components 
indicate that scientific evidence for greater-than-additive or less-than-additive interactions among these 
components is limited and generally inadequate to characterize the possible modes of joint action on most 
of the pertinent toxicity targets.  For two component pairs, cyanide’s effect on the toxicity of uranium 
radiation and nitrate’s effect on cyanide toxicity, less-than-additive effects of the two compounds are 
predicted. For one component pair, fluoride and cyanide, the available data suggest greater-than-additive 
joint action in both directions. No other greater-than-additive or less-than-additive interactions were 
indicated from the available data.  Therefore, it is recommended that additivity be assumed as a public 
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Appendix A. Background Information for Uranium 
A.1 Toxicokinetics 
Studies conducted in human adults indicate that gastrointestinal absorption of ingested soluble uranium 
salts is <5%.  On the basis of studies in animals, absorption of more water soluble uranyl compounds is 
greater than less soluble oxides and tetrahalide compounds.  Studies in animals also provide evidence that 
gastrointestinal absorption of uranium may be increased by fasting and diets deficient in iron, and is 
higher in neonates than in adults. The rate of absorption of uranium compounds deposited in the 
respiratory tract varies with solubility of the uranium compound; more water soluble uranyl compounds 
are absorbed more readily than less soluble oxides and tetrahalide.  Absorbed uranium appears to 
distribute initially to kidney, liver, and other soft tissues; however, under steady state conditions, the 
kidneys and skeleton contain most of the uranium in the body.  Most of the uranium entering the kidney 
and soft tissue is lost over a period of days, but a small amount is retained for years.  Uranium is lost from 
bone in multiple phases having half-lives of days, months, and years.  As a result, the major depot for 
uranium is the bone within months or years after exposure ceases.  Uranium is not known to be 
metabolized.  The uranyl ion forms complexes with bicarbonate, citrate, and other soluble anionic species, 
and binds to proteins in tissue and plasma.  Absorbed uranium is excreted primarily in urine (ATSDR 
1999b). 
Uranium radioisotopes, although they emit alpha radiation, behave in a chemically identical manner 
relative to stable uranium isotopes.  As such, no differences in the kinetics of stable and radioactive 
uranium isotopes are expected, and the kinetics of distribution of the emitted radiation, which has a very 
short path length, can be predicted based on the pharmacokinetic parameters of stable uranium. 
A.2 Health Effects 
Absorbed uranium is nephrotoxic.  Clinical case studies indicate that uranium can produce nephrotoxic 
effects in humans (ATSDR 1999b; Lussenhop et al. 1958).  Epidemiological studies have found 
indications of possible nephrotoxicity (e.g., tubular proteinuria, aminoaciduria, glucosuria, and 
enzymuria) in uranium mill workers and in populations exposed to uranium in well water (ATSDR 
1999b). Nephrotoxicity has been observed in a variety of animal species including dogs, rabbits, and rats 





inhalation route, in dogs, rabbits, and rats subjected to whole-body exposures to air-borne uranium, or 
after parenteral dosing (reviewed in ATSDR 1999b and Diamond 1989).  The functional and 
morphological changes that have been observed in these studies are reasonably consistent across species 
and uranyl salts; these include, depending on the dosage and timing of observations, lesions of the 
glomerulus and renal proximal tubule and a variety of related functional impairments, including decreased 
glomerular filtration and renal blood flow, glucosuria and amino aciduria, proteinuria, and enzymuria. 
Studies of rats and rabbits have shown that ingestion of soluble uranium salts can produce histological 
changes in the thyroid gland and liver lesions in addition to renal lesions (ATSDR 1999b). 
The studies reported in Maynard and Hodge (1949) and Maynard et al. (1953) were conducted as part of 
the health physics program of the Manhattan Project. The reporting of study outcomes focused primarily 
on three indicators of toxicity: growth depression, mortality, and nephrotoxicity, and, despite the above 
limitations, provided data on the relative toxicity of a wide variety of water soluble and relatively water 
insoluble uranium compounds.  In general, studies of rats (the rat was the most extensively explored 
animal model) demonstrated that the more water soluble compounds (e.g., UO2F2, UOs(CH3COO)2@2H2O, 
UO2(NO3)2@6H2O, UO4) have higher toxic potencies than the relatively water insoluble uranium 
compounds (e.g., UO2, UO3, U3O8). Yuile (1973) summarized the relative potency for selected uranium 
compounds as follows, based on a comparison of the dietary concentrations (%) that produced equal body 
weight depressions in the chronic rat studies: UO2F2, 0.25% (155 mg U/kg-day); UO2(NO3)2@6H2O, 
1% (380 mg U/kg-day); UF4, 20% (12,000 mg U/kg-day); and UO2, >20% (>14,000 mg U/kg-day). 
Inhaled uranium particulate can produce lung disease.  A relatively large body of epidemiological 
literature exists on the topic of health outcomes associated with working in the uranium ore mining 
industry (e.g., Bruske-Hohlfeld et al. 1997; Hnizdo et al. 1997; Hornung et al. 1998; Roscoe 1997; 
Roscoe et al. 1995). These studies have shown excess risks of lung cancer and other respiratory tract 
diseases among miners.  Uranium exposures in these populations is to a complex mixture of radon gas 
and daughter isotopes as well as to airborne dusts containing a variety of uranium compounds including 
various water insoluble uranium oxides.  Exposures to radon daughter isotopes are thought to be major 
contributors to the increased risk of diseases of the respiratory tract, including cancer, in uranium miners. 
Health outcomes associated with working in the uranium processing industry also have been studied. 
Here again, exposure in these industries is primarily to dusts of relatively insoluble uranium compounds 
and, possibly, to aerosols of more soluble uranium compounds.  Internal exposure to alpha radiation may 




exposures to uranium dioxide produced nephrotoxic changes and lung fibrosis in dogs and monkeys 
(ATSDR 1999b). 
A small number of studies of the reproductive and developmental effects of uranyl salts have been 
reported (ATSDR 1999b; Paternain et al. 1989). The results of these studies suggest that maternal 
exposures to uranyl acetate during pregnancy can be maternally toxic and fetotoxic. 
Only limited data exist on the toxicity of uranium radiation.  From the standpoint of noncancer effects, the 
effects noted in studies of uranium, even radioisotopes of uranium, are believed to be solely chemical 
(ATSDR 1999b). Although radiation exposure has been generally assumed to be carcinogenic at all dose 
levels, no correlation has been established at low doses such as occur from exposure to natural radiation 
background levels. This is largely attributable to two factors: (1) it is difficult to construct and obtain 
meaningful data from epidemiological studies where exposure is near background exposure levels, and 
(2) the data are not statistically significant enough to substantiate a detectable health impact. 
A.3 Mechanisms of Action 
Mechanisms of uranium-induced nephrotoxicity have been extensively explored in animal models 
(reviewed in Diamond 1989).  Decreased glomerular filtration rate, proteinuria, impairment of tubular 
function, and tubular injury are prominent features of nephrotoxicity in animals exposed to uranyl 
compounds.  Mechanisms for decreased glomerular filtration appear to involve multiple factors including 
changes in renal plasma flow, glomerular capillary hydrostatic pressure, tubular hydraulic pressure, and 
glomerular ultrafiltration coefficient.  Tubular impairments include glucosuria, amino aciduria, 
enzymuria, and osmotic diuresis.  Prominent features of tubular injury are initial necrosis of the terminal 
segments of the proximal tubule with subsequent involvement of the distal tubule.  Tubular impairment 
may represent a combination of direct effects of uranyl ion on transport proteins and the effects of tubular 
necrosis. Mechanisms of proteinuria have not been elucidated, and may have a glomerular and/or tubular 
origin. 
Mechanisms of liver lesions and histological changes in the thyroid observed in rabbits and rats have not 
been elucidated. Mechanisms of uranium-induced lung disease are not completely understood. 
Involvement of inflammation related to the deposition of insoluble particulates in the lung is thought to be 
a contributor where the inhalation exposure is to insoluble uranium compounds.  Radiogenic cancers may 
also arise from local irradiation of lung and lymph tissue from alpha-activity of uranium isotopes. 
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Ionizing radiation, including alpha particles such as are emitted from uranium isotopes, is believed to 
result in ionization events leading to a number of harmful cellular processes, including free radical 
formation, lipid peroxidation, and deoxyribonucleic acid (DNA) damage.  A thorough review of the 
mechanisms of ionizing radiation is found in the ATSDR Toxicological Profile for Ionizing Radiation 
(ATSDR 1999a). 
A.4 Health Guidelines 
ATSDR (1999b) has derived an MRL of 8.0x10-3 mg U/m3 for intermediate-duration inhalation exposure 
to insoluble compounds of uranium based on a no-observed-adverse-effect level (NOAEL) of 
1.1 mg U/m3 for renal effects in dogs (Rothstein 1949b). 
ATSDR (1999b) has derived an MRL of 4.0x10-4 mg U/m3 for intermediate-duration inhalation exposure 
to soluble compounds of uranium based on a lowest-observed-adverse-effect level (LOAEL) of 
0.15 mg U/m3 for renal effects in dogs (Rothstein 1949a). 
ATSDR (1999b) has derived an MRL of 3.0x10-4 mg U/m3 for chronic-duration inhalation exposure 
(365 days or more) to soluble compounds of uranium based on a NOAEL of 0.05 mg U/m3 for renal 
effects in dogs (Stokinger et al. 1953). 
ATSDR (1999b) has derived an MRL of 2.0x10-3 mg/kg/day for intermediate-duration oral exposure to 
soluble compounds of uranium based on a LOAEL of 0.05 mg U/kg/day for renal effects in rabbits 
(Gilman et al. 1998).  This MRL was considered to be protective for chronic exposures as well. 
EPA established a chronic oral RfD of 3x10-3 mg U/kg-day for soluble uranium salts (IRIS 2002).  The 
RfD is based on weight loss and nephrotoxicity in rabbits observed in a 30-day feeding study (Maynard 
and Hodge 1949). EPA (IRIS 2002) has not established a chronic inhalation reference concentration 
(RfC) or cancer risk assessment for uranium compounds. 
EPA (1995) has established slope factors for carcinogenicity from ingestion or inhalation of radioisotopes 
of uranium (EPA 1995).  EPA (1999) also has established risk coefficients for radiogenic cancer 
morbidity and mortality from inhalation, tap water, and dietary intakes of radioisotopes of uranium. 
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A.5 Derivation of Target-Organ Toxicity Dose (TTD) Values 
TTDs for chronic oral exposure to uranium were derived for endpoints affected by one or more of the 
other chemicals in the uranium, fluoride, cyanide, and nitrate mixture that is the subject of this Interaction 
Profile. The relevant endpoints for this mixture include renal, neurological, and reproductive (testicular) 
effects. Where data are available, chronic oral TTDs for these endpoints are derived below, using the 
methods described in ATSDR (2001c, Section 2.3.2).  Of the endpoints of concern for the mixture, data 
are available only for renal effects of uranium. The derivations are based on data presented in ATSDR 
(1999b). Due to inadequate data, TTDs were not derived for uranium radiation. 
Renal Effects 
ATSDR (1999b) has derived an MRL of 2.0x10-3 mg/kg/day for intermediate-duration oral exposure, and 
stated that this MRL is likely to be protective for chronic-duration oral exposure, to soluble compounds of 
uranium based on a LOAEL of 0.05 mg U/kg/day for renal effects in rabbits (Gilman et al. 1998).  The 
MRL was derived by applying an uncertainty factor of 30 (3 for use of a minimal LOAEL and 10 for 
intrahuman variability) to the LOAEL. 
Summary (TTDs for Uranium) 
MRLRENAL = 2x10-3 mg/kg/day 
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Appendix B. Background Information for Fluoride 
B.1 Toxicokinetics 
Studies on the rate and extent of fluorine absorption are not available, but evidence suggests that fluorine 
is too reactive to be absorbed unchanged, and instead is absorbed as fluoride.  A study in rats suggests 
that hydrogen fluoride is absorbed primarily by the upper respiratory tract, and that removal of hydrogen 
fluoride from inhaled air by the upper respiratory tract approaches 100% for exposures that range from 
30 to 176 mg fluoride/m3 (Morris and Smith 1982).  The studies of Collings et al. (1951) and Rye (1961) 
have demonstrated the absorption of fluoride from fluoride-containing dusts, but did not quantify the rate 
or extent of the absorption. 
Ingested dietary fluoride is readily absorbed from the gastrointestinal tract as the undissociated hydrogen 
fluoride molecule by passive absorption (Whitford and Pashley 1984).  Since the neutral undissociated 
molecule can penetrate cell membranes and be absorbed much better than the fluoride ion, decreasing the 
stomach pH increases absorption.  The absorption of soluble fluoride in humans is rapid and extensive 
(~97%) (ATSDR 2001d) with maximum plasma fluoride concentrations attained as early as within 
30 minutes following exposure (Ekstrand et al. 1977).  However, additional factors can affect absorption. 
For example, the absorption of fluoride as calcium fluoride is increased when the material is given with 
meals (Trautner and Einwag 1987). 
Following absorption, distribution of fluoride to the blood is rapid. Immediately following 40 minutes of 
intermittent inhalation exposure, plasma fluoride concentrations correlated closely (correlation 
coefficient=0.98; p<0.01) with the concentration of hydrogen fluoride in the air passed through the 
surgically isolated upper respiratory tract.  Plasma levels were not measured at time points <40 minutes. 
Reports of skeletal fluorosis and elevated bone fluoride levels after occupational exposure to hydrogen 
fluoride and fluoride dusts indicate that fluoride is distributed to bone, mainly in regions undergoing 
active ossification or calcification, and accumulates there after inhalation exposure (ATSDR 2001d). 
Long-term retention and accumulation of fluoride are primarily confined to calcified tissue in humans, 
though soft tissue concentrations of fluoride do rise transiently following ingestion of fluoride (ATSDR 
2001d). Teeth and bone readily take up fluoride following oral exposure (ATSDR 2001d).  While the 
rate of fluoride uptake in human teeth may decrease with age, it is apparent that the total fluoride content 
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of teeth and bone increases throughout life, and that the amount deposited is dependent on the exposure 
concentration. With the exception of the aorta and kidney, there is no evidence of accumulation or 
retention of fluoride in soft tissues in humans (ATSDR 2001d).  Upon cessation of exposure, fluoride 
levels in bone are expected to decrease slowly; however, the time period over which this would occur in 
humans is not known. 
Fluoride is believed to replace the hydroxyl ion and possibly the bicarbonate ion associated with 
hydroxyapatite—a mineral phase during formation of bone (ATSDR 2001d).  The resultant material is 
hydroxyfluorapatite.  Once absorbed, a portion of the fluoride is deposited in the skeleton, and the 
remainder is excreted in the urine, feces, sweat, and saliva within 24 hours (ATSDR 2001d).  Thus, 
skeletal sequestration and renal excretion are the two major means by which the body prevents circulation 
of toxic amounts of fluoride ion.  Fluoride in the skeleton is removed approximately at the rate of bone 
remodeling.  Urinary excretion is markedly decreased in the presence of decreased renal function 
(ATSDR 2001d). 
The fluoride ion carried in human blood serum exists in two forms, namely as an inorganic ion F- and in 
combination with an organic molecule (Halton et al. 1984).  The toxicological significance, if any, of the 
latter form is unknown.  A portion of the circulating inorganic fluoride acts as an enzyme inhibitor 
because it forms metal-fluoride-phosphate complexes that interfere with the activity of those enzymes 
requiring a metal ion cofactor.  In addition, fluoride may interact directly with the enzyme or the 
substrate. It is a general inhibitor of the energy production system of the cell, and of glycolysis in 
particular (ATSDR 2001d). Although much is known about enzyme inhibition by fluoride, the human 
health significance remains to be determined.  The studies on enzymatic inhibition by fluoride were 
in vitro studies and used fluoride concentrations that were significantly higher than concentrations that 
would be normally found in human tissues. 
No data were located regarding excretion of fluoride following human inhalation exposure to fluorine. 
Urinary fluoride levels were increased in dogs and rabbits exposed to levels as low as 0.8 mg/m3 for 
5–6 hours/day, 6 days/week for 35 days (Stokinger 1949).  No quantitative data were reported at this 
level, but urinary fluoride levels in rabbits exposed to 3 mg/m3 were 1.5 times normal.  Studies in humans 
indicate that fluoride absorbed from inhaled hydrogen fluoride over an 8-hour work shift is excreted even 
during exposure, with urinary excretion peaking approximately 2–4 hours after cessation of exposure 
(about 10 hours following beginning of exposure) (Collings et al. 1951; Rye 1961). 
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The principal route of elimination of ingested fluoride is via the urine as demonstrated in a variety of 
species. In general, urine accounts for about 50–70% of the fluoride intake and feces accounts 
for 5–10%.  Estimates of total elimination range from about 50% (Spencer et al. 1970) to about 100% 
(McClure et al. 1945). These varying estimates lead to widely varying estimates of the amount of 
fluoride that is stored in the body.  There is a striking linear relationship between the concentration of 
fluoride in drinking water and in the urine of humans exposed continuously to fluoride.  However, plasma 
fluoride levels are reflected better by the urinary fluoride excretion rate than by the concentration of 
fluoride in the urine (Ekstrand and Ehrnebo 1983).  Large amounts of fluoride were excreted for 
prolonged periods by persons who lived for many years in areas with high fluoride water levels and who 
subsequently moved to areas with low fluoride levels, which indicated the excretion of fluoride that was 
mobilized from bone (Likins et al. 1962). 
B.2 Health Effects 
The primary effects of fluorides following acute inhalation exposure consist of irritation of the respiratory 
tract, with hematologic, renal, and hepatic effects seen in animal studies.  Humans exposed to fluorine, 
which is thought to be rapidly converted to fluoride upon contact with tissues, have reported nasal 
irritation at exposures as low as 50 parts per million (ppm) for 3 minutes (Keplinger and Suissa 1968). 
Animal studies have established 60-minute 50% lethal concentration (LC50) values ranging from 
150 to 185 ppm for fluorine and from 325 to 1,610 ppm for hydrogen fluoride (ATSDR 2001d).  Effects 
following subchronic inhalation to fluorine and hydrogen fluoride are similar to the acute effects, with 
nasal irritation being the most sensitive effect reported in humans, and respiratory tract irritation, 
hemorrhage, and edema being the most sensitive effects seen in animal studies (ATSDR 2001d).  No 
studies of the health effects of chronic inhalation exposure to fluoride in humans or animals were 
identified. 
Eichler et al. (1982) reported that a 3-year-old boy who had consumed a single dose of 16 mg fluoride/kg 
died 7 hours following ingestion. Upon autopsy, hemorrhagic edema of the lungs, hemorrhagic gastritis, 
and massive cerebral edema were observed.  The hemorrhagic edema observed in the lungs was probably 
due to aspiration of the gastric contents. Cloudy swelling was observed in the cells of the liver, heart, and 
kidney.  In rats, LD50 values for sodium fluoride administered by oral gavage range from 31 to 101 mg 
fluoride/kg (ATSDR 2001d). These LD50 values for rats may vary with strain, weight, and gender.  An 
LD50 of 44.3 mg fluoride/kg was reported for mice (Lim et al. 1978).  No reproductive effects were seen 
in mice exposed for 5 days to 32 mg fluoride/kg/day, nor were developmental effects reported in rats 
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exposed to 12.26 mg fluoride/kg/day on gestational days 6–15 or in mice exposed to 13.21 mg 
fluoride/kg/day (ATSDR 2001d). 
Data are not available on the effects of intermediate-duration exposure to fluoride in humans. 
Intermediate-duration exposure of animals to fluoride has resulted in effects on a number of organ 
systems, including bone, testes, kidney, neurobehavioral effects, and developmental effects.  Effects on 
the bone are commonly reported, including decreased bone growth, alterations in tooth enamel, delayed 
bone healing, and increased bone formation rate.  A number of studies in rats, mice, and guinea pigs have 
reported testicular effects, including reduced fertility, decreased sperm counts, and histologic alterations 
of the seminiferous tubules and Leydig cells.  Two studies in rats have demonstrated alterations in 
spontaneous behavior and decreased spontaneous activity in rats exposed for 6 weeks or 60 days, while 
two studies in mice have demonstrated renal effects of ingested fluoride.  A study in rats reported that 
exposure of dams to 11.4 mg fluoride/kg/day resulted in an increased number of fetuses per litter with 
skeletal variations—no other developmental effects of fluoride were identified (ATSDR 2001d). 
An extensive database on the effects of oral exposure to fluoride in humans exists, identifying effects on 
bone as the most sensitive effect of chronic exposure (ATSDR 2001d).  Numerous studies have examined 
the possible relationship between chronic exposure to fluoride in drinking water and the risk of bone 
fractures. Many of these studies examined communities with high level of fluoride in the water or 
fluoridated water (ATSDR 2001d); a few prospective or retrospective studies have also examined this 
possible association. These studies have found conflicting results, with studies finding a lower or higher 
incidence of hip fractures or no differences in hip fracture between humans exposed to fluoride in 
drinking water. The chronic oral MRL is based on a LOAEL of 0.56 mg fluoride/kg/day for increased 
fracture rates in osteoporotic postmenopausal women. 
Fluoride results in thickened bones and exostoses (skeletal fluorosis) when ingested in large doses for an 
extended period of time (ATSDR 2001d).  Signs of skeletal fluorosis range from increased bone density 
to severe deformity, known as crippling skeletal fluorosis.  Crippling fluorosis is characterized by 
complete rigidity of the spine, often accompanied by kyphosis (humpback) or lordosis (arched back). 
Reported cases are found almost exclusively in developing countries, particularly India, and are 
associated with malnutrition.  The incidence of early skeletal fluorosis in the United States is unknown, 
since it appears that the early signs can only be identified radiologically.  Fluoride may also have effects 
on the kidney, with a case report demonstrating that exposure to high levels of fluoride resulted in renal 
insufficiency and interstitial nephritis (ATSDR 2001d). 
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While animal studies, particularly in minks, have confirmed the toxicity of fluoride in bone, chronic oral 
studies in animals have also identified effects of fluoride in organs other than bone (ATSDR 2001d). 
Rabbits exposed to 5 mg fluoride/kg/day as sodium fluoride showed a roughened duodenal mucosa, while 
exposure of rabbits to 4.5 mg fluoride/kg/day as sodium fluoride resulted in serious testicular effects, with 
structural damage to the developing spermatids and a complete cessation of spermatogenesis, as well as 
decreased levels of total primary and secondary antibody titers, suggesting an impaired immune response. 
Numerous epidemiological studies have examined the issue of a connection between fluoridated drinking 
water and cancer. The weight of evidence indicates that no such connection exists.  However, all of the 
investigations were ecologic studies, and the sensitivity limit of even the most sensitive analysis in these 
studies appears to be a 10–20% increase. Since any carcinogenic effect of fluoride at the levels found in 
water supplies would probably be below this level of sensitivity, a National Toxicology Program (NTP) 
cancer bioassay was conducted to assess the effect of fluoride in the drinking water on cancer incidence in 
animals (Bucher et al. 1991; NTP 1990).  The NTP study found equivocal evidence of a fluoride-related 
increase in osteosarcomas in male rats, and no evidence of any fluoride-related neoplasm in female rats or 
male or female mice.  A lifetime oral study sponsored by Proctor and Gamble (Maurer et al. 1990) found 
no evidence of fluoride carcinogenicity in either male or female rats exposed in the feed.  Both studies 
contain limitations that preclude strong conclusions.  The NTP is presently carrying out additional 
experiments on the relationship, if any, between fluoride and cancer. 
B.3 Mechanisms of Action 
A number of mechanisms are involved in the toxicity of fluoride to bone.  Fluoride ions are incorporated 
into bone by substituting for hydroxyl groups in the carbonate-apatite structure to produce hydroxy­
fluorapatite, thus altering the mineral structure of the bone (Chachra et al. 1999).  Unlike hydroxyl ions, 
fluoride ions reside in the plane of the calcium ions, resulting in a structure that is electrostatically more 
stable and structurally more compact (Grynpas and Rey 1992).  Following administration of fluoride, 
there is a shift in the mineralization profile towards higher densities and increased hardness (Chachra 
et al. 1999). Although fluoride administration is associated with an increase in bone mass, in vivo and 
in vitro animal studies have found a negative association between fluoride-induced new bone mass and 
bone strength, suggesting that the quality of the new bone was impaired by the fluoride (ATSDR 2001d). 
Because bone strength is thought to derive mainly from the interface between the collagen and the 
mineral (Catanese and Keavney 1996), alteration in mineralization probably affects strength.  The wider 
crystals, which are formed after fluoride exposure, are presumably not associated with collagen fibrils and 
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thus, do not contribute to mechanical strength.  Turner et al. (1997) found that the crystal width was 
inversely correlated with bending strength of the femur.  Thus, although there is an increase in hardness 
and bone mass and unaltered structure, the mechanical strength of bone is decreased (Chachra et al. 
1999). 
In addition to the physicochemical effect of fluoride on the bone, at high doses, fluoride can be mitogenic 
to osteoblasts (ATSDR 2001d) and inhibitory to osteoclasts.  The osteoblasts are still active, although 
there are fewer plump, cuboidal, highly secretory osteoblasts; whereas fluoride is mitogenic to osteo­
blastic precursors (Bonjour et al. 1993), it is toxic to individual osteoblasts at the same concentration 
(Chachra et al. 1999). The effect of fluoride on osteoclasts is not well understood; it appears that fluoride 
decreases the amount of bone resorbed by osteoclasts (Chachra et al. 1999). 
Studies in humans and animals suggest that the effect of fluoride on bone strength is biphasic.  In rats 
administered 1–128 ppm fluoride as sodium fluoride in drinking water for 16 weeks, both increases and 
decreases in bone strength were found; the maximum femoral bone strength occurred at 16 ppm (Turner 
et al. 1992). A biphasic relationship between femoral bone strength and bone fluoride content was found. 
The biphasic nature of bone effects is supported by data from clinical trials in women with post­
menopausal osteoporosis (Haguenauer et al. 2000).  The meta-analyses of 12 studies found a significant 
increase in the relative risk of nonvertebral fractures in subjects ingesting high doses of fluoride; in 
subjects administered low fluoride doses or slow-release formulations, there was no effect on 
nonvertebral fractures. Similarly, there was no effect on vertebral fracture risk in high fluoride dose 
subjects, but a decrease in this risk in subjects administered low fluoride doses or slow-release 
formulations was found. 
Fluoride has been shown to interfere with glycolysis.  Because the central nervous system relies heavily 
on this energy source, hypotheses have been advanced as to a mechanism for fluoride effects on the 
central nervous system.  Although effects on glycolytic enzymes could explain the neuromuscular 
symptoms seen frequently in cases of fluoride poisoning (e.g., tetany, paresthesia, paresis, convulsions), 
other studies tend to indicate that hypocalcemia caused by fluoride binding of calcium causes these 
symptoms. 
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B.4 Health Guidelines 
ATSDR (2001d) derived an acute inhalation MRL of 0.01 ppm for fluorine, based on a NOAEL of 
10 ppm for irritation of the eyes and skin during a 15-minute exposure of volunteers.  The NOAEL was 
adjusted for a 24-hour continuous exposure, and an uncertainty factor of 10 for intrahuman variability 
was applied to yield the MRL of 0.01 ppm. 
ATSDR (2001d) also derived an acute inhalation MRL of 0.03 ppm fluoride for hydrogen fluoride, based 
on a NOAEL of 98 ppm fluoride for nasal irritation in rats exposed for 60 minutes.  The NOAEL was 
converted to a human equivalent concentration, duration-adjusted, and an uncertainty factor of 30 (3 for 
animal to human extrapolation using dosimetric adjustment, and 10 for intrahuman variability) to give the 
MRL of 0.03 ppm fluoride. 
An intermediate-duration inhalation MRL of 0.02 ppm fluoride (ATSDR 2001d) was derived for 
hydrogen fluoride based on a duration-adjusted LOAEL of 0.75 ppm fluoride for slight irritation of the 
respiratory tract in volunteers exposed to hydrogen fluoride for 15–50 days.  An uncertainty factor of 
30 (3 for use of a minimal LOAEL and 10 for intrahuman variability) was applied to the LOAEL to 
derive the MRL of 0.02 ppm fluoride. 
No inhalation MRLs were derived for fluorides other than hydrogen fluoride. No chronic inhalation 
MRLs were derived for fluorine or hydrogen fluoride (ATSDR 2001d). 
No oral MRLs were derived for fluorine or hydrogen fluoride (ATSDR 2001d). 
No acute or intermediate MRLs were derived for fluoride (ATSDR 2001d). 
A chronic-duration oral MRL of 0.06 mg fluoride/kg/day was derived for fluoride (ATSDR 2001d), based 
on a LOAEL of 0.56 mg fluoride/kg/day for increased fracture rate in osteoporotic postmenopausal 
women.  The MRL was derived by applying an uncertainty factor of 10 for use of a LOAEL in a sensitive 
human subpopulation. 
EPA has derived an oral RfD of 0.06 mg/kg/day for fluoride (ATSDR 2001d), based on a NOAEL of 
0.06 mg/kg/day for dental fluorosis in chronically-exposed children (Hodge 1950).  An uncertainty factor 
of 1 was applied to the NOAEL since the study was a chronic study in a sensitive population of humans. 
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No RfC for fluoride has been derived, and fluoride has not undergone an evaluation of carcinogenic 
potential by EPA. 
B.5 Derivation of Target-Organ Toxicity Dose (TTD) Values 
TTDs for chronic oral exposure to fluoride were derived for endpoints affected by one or more of the 
other chemicals in the uranium, fluoride, cyanide, and nitrate mixture that is the subject of this Interaction 
Profile. The relevant endpoints for this mixture include renal, neurological, and reproductive (testicular) 
effects. Where data are available, chronic oral TTDs for these endpoints are derived below, using the 
methods described in ATSDR (2001c, Section 2.3.2).  The derivations are based on data presented in 
ATSDR (2001d). 
Musculoskeletal Effects 
A number of human studies have investigated the toxicity, particularly potential skeletal toxicity, of 
fluoride (for review of these studies, see ATSDR 2001d). The vast majority of these studies were 
ecological studies examining the possible relationship between fluoride in drinking water and the 
occurrence of hip fractures. These studies, as well as retrospective cohort studies, have found decreases, 
increases, and no effect on hip fracture occurrence in communities consuming fluoridated water. 
Limitations in the study designs of many of these studies preclude using these data to establish a causal 
relationship between fluoride and risk of hip fractures.  In addition to these epidemiology studies, several 
human experimental studies have examined the effect of fluoride administration for the treatment of 
osteoporosis. One study found significant increases in lumbar spine and femoral head and trochanter 
bone mineral density, decreases in radius bone mineral density, no effect on vertebral fracture rate, and 
increases in nonvertebral fracture rate among postmenopausal women with osteoporosis ingesting a 
capsule containing 34 mg fluoride/day as sodium fluoride for 4–6 years.  Another study did not find any 
effect on bone mineral density or vertebral or nonvertebral fracture rates among postmenopausal women 
with spinal osteoporosis ingesting 34 mg fluoride/day as sodium fluoride.  A meta-analysis of these data, 
as well as other clinical studies, found a significant correlation between exposure to high levels of 
fluoride and an increased relative risk of nonvertebral fractures. The LOAEL of 34 mg fluoride/day 
(0.56 mg fluoride/kg/day) was selected as the basis of a chronic-duration oral MRL for fluoride.  The 
MRL of 0.06 mg fluoride/kg/day was derived by dividing the LOAEL by an uncertainty factor of 10 to 




Greenberg (1982) reported a LOAEL of 1.9 mg fluoride/kg/day for degeneration of the nephron in mice 
exposed to sodium fluoride in the drinking water for 280 days.  To this LOAEL, an uncertainty factor of 
100 (10 for animal to human extrapolation and 10 for intrahuman variability) was applied to yield a 
provisional TTDRENAL of 2x10-2 mg/kg/day.  However, as this value, derived from animal data, is lower 
than the chronic MRL of 0.06 mg/kg/day, which is based on chronic human data examining the most 
sensitive known endpoint of fluoride toxicity, the MRL value of 0.06 mg/kg/day was adopted as the 
TTDRENAL for fluoride. 
Reproductive Effects 
In CD rats exposed to sodium fluoride for 60 days in the diet, Araibi et al. (1989) reported a LOAEL of 
2.3 mg fluoride/kg/day for alterations in the seminiferous tubule diameter.  To this LOAEL, an 
uncertainty factor of 1,000 (10 for a LOAEL, 10 for animal to human extrapolation, and 10 for 
intrahuman variability) to yield a provisional TTDREPRO of 2x10-3 mg/kg/day.  However, as this value, 
derived from animal data, is lower than the chronic MRL of 0.06 mg/kg/day, which is based on chronic 
human data examining the most sensitive known endpoint of fluoride toxicity, the MRL value of 
0.06 mg/kg/day was adopted as the TTDREPRO for fluoride. 
Neurological Effects 
Mullenix et al. (1995) identified a NOAEL of 5.5 mg fluoride/kg/day and a LOAEL of 7.5 mg 
fluoride/kg/day for alterations in spontaneous behavior in Sprague-Dawley rats exposed to sodium 
fluoride in the drinking water for 6 weeks. To this LOAEL, an uncertainty factor of 1,000 (10 for a 
LOAEL, 10 for animal to human extrapolation, and 10 for intrahuman variability) to yield a provisional 
TTDNEURO of 5x10-3 mg/kg/day.  However, as this value, derived from animal data, is lower than the 
chronic MRL of 0.06 mg/kg/day, which is based on chronic human data examining the most sensitive 




Summary (TTDs for Fluoride) 
TTDRENAL = 0.06 mg/kg/day 
TTDREPRO = 0.06 mg/kg/day 
TTDNEURO = 0.06 mg/kg/day 
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Appendix C. Background Information for Cyanide 
C.1 Toxicokinetics 
Cyanide is rapidly absorbed (within seconds) following inhalation exposure.  Humans retained 58% of 
hydrogen cyanide in the lungs after inhaling the gas through normal breathing (Landahl and Herrmann 
1950). During inhalation exposure of dogs to an unknown concentration of hydrogen cyanide (Gettler 
and Baine 1938), one dog reportedly absorbed 16.0 mg (1.55 mg/kg); the other dog absorbed 10.1 mg 
(1.11 mg/kg).  These doses were fatal to the dogs in 15 and 10 minutes, respectively.  More recent 
quantitative data were not available. Following oral exposure, cyanide is rapidly absorbed, as evidenced 
by the death of an exposed dog as early as 8 minutes following exposure (Gettler and Baine 1938); the 
absorption of cyanide varied from 17 to 74% in the three exposed dogs.  A more recent study in rats 
(Farooqui and Ahmed 1982) indicated that at least 53% of a single oral dose of cyanide in rats was 
absorbed within 24 hours of exposure. Evidence for dermal absorption of cyanide comes from studies in 
animals (ATSDR 1997) wherein systemic toxicity was observed following dermal contact with cyanide 
compounds; however, quantitative data on the dermal absorption of cyanide are not available. 
Following absorption, cyanide is rapidly distributed by the blood throughout the body.  After inhalation 
exposure in humans, tissue cyanide levels, expressed per gram of wet tissue, were highest in the lung, 
followed by the heart, blood, kidney, brain, and liver (ATSDR 1997).  Similar distribution patterns were 
seen in animals after cyanide inhalation.  In humans who had died of oral cyanide overdose, cyanide 
levels were generally greatest in the stomach contents, with significant levels reported in the spleen, 
lungs, blood, liver, brain, and kidney (ATSDR 1997).  Following oral exposure in animals, a similar 
pattern was seen, with the greatest levels in the stomach contents, with significant levels in the liver, lung, 
blood, and kidney (ATSDR 1997).  Cyanide in the blood was found mainly (95%) in the hemolysate, with 
70% of the total cyanide found in the heme-containing fraction (Farooqui and Ahmed 1982).  Cyanide 
has not been reported to accumulate in the body. 
Reports of ingestion of cyanides by humans and reports of occupational exposure indicate that cyanide is 
transformed into thiocyanate.  A plasma half-life of 20 minutes to 1 hour has been estimated for cyanides 
in humans after nonlethal exposures (Hartung 1982).  Animal data indicate that the primary pathway of 
cyanide metabolism involves transformation to thiocyanate by either rhodanese or 3-mercaptopyruvate 
sulfur transferase, accounting for 60–80% of the administered dose (ATSDR 1997).  Species and tissue 
 
54 
distribution of rhodanese is highly variable, with dogs possessing the lowest levels of all species 
examined (Himwich and Saunders 1948).  Minor pathways of cyanide metabolism include (1) conversion 
to 2-aminothiazoline-4-carboxylic acid; (2) incorporation into a 1-carbon metabolic pool; or 
(3) combining with hydroxocobalamin to form cyanocobalamin (vitamin B12). 
Cyanide metabolites are normally excreted in urine with small amounts eliminated through the lungs. 
Urinary excretion of thiocyanate was monitored in a man after ingestion of ~3–5 grams of potassium 
cyanide (15–25 mg CN-/kg) (ATSDR 1997). The results indicated that the patient excreted 237 mg of 
thiocyanate over a 72-hour period.  This quantity was substantially more than the normal average amount 
of thiocyanate in urine, which varies between 0.85 and 14 mg/24 hours.  Thirty-one children who had 
consumed flour made from insufficiently processed cassava, which therefore had significant 
concentrations of cyanide, had mean urinary thiocyanate levels of 757 :mol/L, compared with 50 :mol/L 
in those children who had consumed sufficiently processed cassava.  When rats were given 2 mg CN-/kg 
of radiolabeled potassium cyanide, urinary excretion of radioactivity reached 47% of the dose within 
24 hours following administration.  When [14C] sodium cyanide was injected subcutaneously into rats at a 
level of 8.3 :mol, no difference in radioactivity eliminated was observed between the group pretreated for 
6 weeks with a diet containing 0.7 mg CN-/kg as potassium cyanide and their matching controls.  Most of 
the radioactivity was detected in the urine (89% by 24 hours).  Thiocyanate was the major metabolite. 
About 4% of the radioactivity was expired, mostly as carbon dioxide. 
C.2 Health Effects 
Studies of the acute effects of cyanide inhalation have generally been limited to the examination of 
serious and lethal effects. Acute inhalation exposure to high levels of cyanide, regardless of the form, 
leads quickly to death that is preceded by dyspnea, convulsions, and central nervous system depression 
(ATSDR 1997). A human 10-minute LC50 of 524 ppm for cyanide inhalation has been estimated 
(ATSDR 1997), while Singh et al. (1989) reported that a man exposed to 192 ppm died within 3 days of 
exposure. Rat LC50 values of 483 ppm cyanide for a 5-minute exposure and 137 ppm cyanide for a 
60-minute exposure have been reported (ATSDR 1997).  Mouse LC50 levels are similar to those in rats, 
with LC50 values of 310 ppm cyanide for a 5-minute exposure and 159 ppm cyanide for a 30-minute 
exposure (ATSDR 1997). Other acute effects of cyanide inhalation include peripheral vision loss in a 
male human exposed for 13 minutes to 434 ppm cyanide as hydrogen cyanide and dyspnea, bradycardia, 
arrhythmia, and EEG alterations in monkeys exposed for 30 minutes to 96 ppm cyanide as hydrogen 
cyanide. 
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Data on the effects of subchronic or chronic inhalation exposure to cyanide in humans and animals are 
limited.  In an early study, four dogs were exposed to 43 ppm cyanide as hydrogen cyanide for 
30 minutes every other day for 28 days.  One dog of four died, while other affected endpoints included 
the respiratory (dyspnea), gastrointestinal (vomiting, tenesmus, and diarrhea), and neurological (tremors, 
ataxia, stiffness, cellular atrophy) effects.  A later study reported increased creatine phosphokinase 
activity in rats following five 12.5-minute exposures, at 4-day intervals, to 192 ppm cyanide as hydrogen 
cyanide (ATSDR 1997). 
Two chronic studies of humans occupationally exposed to cyanide are reported in ATSDR (1997). 
El Ghawabi et al. (1975) described a cohort of workers chronically exposed (5–15 years) to 6.4–10.4 ppm 
of an unspecified cyanide form evolved from sodium cyanide and copper cyanide during electroplating. 
Reported symptoms included dyspnea, lacrimation, precordial pain, increased hemoglobin and 
lymphocytes, and vomiting, as well as significant neurological effects, including confusion, hallucination, 
headache, weakness, and dizziness. A later study (Blanc et al. 1985) described health effects in workers 
exposed to 15 ppm hydrogen cyanide (14 ppm cyanide) in a silver-reclaiming facility.  Symptoms were 
similar to those reported by El Ghawabi et al. (1975), and included dyspnea, palpitations, chest pain, 
nausea, altered thyroid hormone levels, rash, decreased body weight, and neurologic effects, including 
persistent headache, dizziness, and paresthesia. Both of these studies, however, are limited by their 
inability to control for co-exposure to other compounds. 
Case reports of acute oral exposures to cyanide in humans have identified a number of health effects. 
Stertorous, deep, and rapid breathing was reported in a man who ingested ~15 mg CN- /kg as potassium 
cyanide in a suicide attempt (Liebowitz and Schwartz 1948), while shortness of breath and dyspnea were 
observed in two reports of suicide attempts; one man ingested 7.6 mg CN-/kg (Goodhart 1994) and the 
other man ingested 0.57 mg CN-/kg (Saincher et al. 1994), both as potassium cyanide.  Acute neurologic 
effects vary with the amount of cyanide consumed, ranging from headache at low doses, to tremor and 
coma at higher doses (ATSDR 1997).  There is evidence that acute oral exposures to cyanide can lead to 
the development of Parkinsonism (ATSDR 1997).  Other reported effects of acute oral cyanide exposure 
in humans include shallow pulse, albuminuria, increased serum creatinine and serum creatinine kinase, 
and metabolic acidosis (ATSDR 1997).  Hamsters exposed from gestational days 3–14 showed no effects 
on the number of implantations or resorptions at concentrations up to 10.4 mg CN/kg/day as cassava, but 
1 mg CN/kg/day as cassava resulted in significantly decreased fetal weight and delayed bone ossification 




Studies of humans orally exposed to cyanide for intermediate duration are lacking.  The intermediate-
duration oral MRL for cyanide is based on a 13-week drinking water study performed by NTP (1993) 
which defined a NOAEL of 4.5 mg/kg/day and a LOAEL of 12.5 mg/kg/day for decreased weights of 
male reproductive organs and altered spermatogenesis in male F344 rats.  The study did not report effects 
on other organ systems, including neurological effects, in rats at doses up to 12.5 mg/kg/day or in mice at 
doses up to 24.3 mg/kg/day in males and 28.8 mg/kg/day in females.  In contrast, Gerhart (1986, 1987a, 
1987b) reported altered posture and hypoactivity in Sprague-Dawley rats exposed by gavage for 90 days 
to 0.8 mg CN/kg/day as KAg(CN)2 or 0.14 mg CN/kg/day as CuCN, with labored respiration seen at 
0.8 mg CN/kg/day as KAg(CN)2 or 4.35 mg CH/kg/day as CuCN.  Gerhart (1986, 1987a, 1987b) also 
reported increased testicular weight at 2.6 mg CN/kg/day as KAg(CN)2 or 14.5 mg CN/kg/day as CuCN. 
A 14-week study in male dogs identified LOAELs of 1.04 mg CN/kg/day, regardless of whether the food 
contained NaCN or cassava, for cardiac swelling and hemorrhage, proximal tubule damage, kidney 
congestion and vacuolation, adrenal cortex swelling and fibrosis, and destruction of germ cells in the 
seminiferous tubules (Kamalu 1993).  However, as dogs have very low levels of rhodanese relative to 
humans, and thus a higher sensitivity to the effects of cyanide, the implication of these studies relative to 
risks in humans is uncertain. 
Data on the effects of chronic oral exposure to cyanide, including studies of carcinogenicity, in humans 
and animals are lacking. 
C.3 Mechanisms of Action 
Cyanide (as hydrogen cyanide), originating in vivo by dissociation of potassium cyanide, sodium cyanide, 
and other cyanogenic compounds or arising from catabolism of cyanogenic glycosides, exerts its acute 
toxic effects by complexing with the ferric iron atom in metalloenzymes, resulting in histotoxic anoxia 
through inhibition of cytochrome c oxidase (ATSDR 1997), metalloenzymes that function as the terminal 
oxidase of the inner mitochondrial membrane respiratory chain.  A two-step process has been proposed: 
cyanide as hydrogen cyanide first penetrates a protein crevice of cytochrome c oxidase and binds to the 
protein. Hydrogen cyanide then binds to the trivalent iron ion of the enzyme, forming a relatively stable 
(but reversible) coordination complex.  One mole of hydrogen cyanide is bound to one mole of 
cytochrome c oxidase.  As a result, the enzyme becomes unable to catalyze the reactions in which 
electrons would be transferred from reduced cytochrome to oxygen.  Cellular oxygen utilization is thus 
impaired, with resultant reduction in or cessation of aerobic metabolism (ATSDR 1997).  Glucose 
catabolism then shifts from the aerobic pathway to anaerobic metabolism including the pentose phosphate 
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pathway, resulting in increased blood glucose, pyruvic acid, lactic acid, and nicotinamide adenine 
dinucleotide phosphate (NADPH) levels, and a decrease in the adenosine triphosphate/adenosine 
diphosphate (ATP/ADP) ratio. 
The inhibition of oxygen use by cells (termed histoxic hypoxia) causes oxygen tensions to rise in 
peripheral tissues. This results in a decrease in the unloading gradient for oxyhemoglobin; thus, 
oxyhemoglobin is carried in the venous blood.  Inhibition of oxygen utilization is thought to occur rapidly 
after cyanide exposure (ATSDR 1997).  Tadic (1992) determined that inhibition of cytochrome c oxidase 
activity in rat brains was most pronounced between 15 and 20 minutes after administration of sodium 
cyanide (12 mg/kg or 1.3xLD50). In addition to binding to cytochrome c oxidase, cyanide also binds to 
catalase, peroxidase, methemoglobin, hydroxocobalamin, phosphatase, tyrosinase, ascorbic acid oxidase, 
xanthine oxidase, and succinic dehydrogenase. 
The central nervous system is the primary target for acute cyanide toxicity in humans and animals.  Acute 
inhalation of high concentrations of cyanide provokes a brief central nervous system stimulation followed 
by depression, convulsions, coma, and death in humans and in animals (ATSDR 1997).  The effects are 
probably due to rapid biochemical changes in the brain, such as changes in ion flux, neurotransmitter 
release, and possibly peroxide formation (ATSDR 1997). 
Cyanide poisoning likely involves mechanisms in addition to inhibition of cytochrome c oxidase activity. 
Cyanide is a strong nucleophile with multiple effects including release of secondary neurotransmitters, 
release of catecholamines from adrenal glands and adrenergic nerves, and inhibition of antioxidant 
enzymes in the brain.  However, the extremely low concentration of cyanide required to inhibit the 
oxidase, the rapid interaction of hydrogen cyanide with the enzyme and the key role of cytochrome 
c oxidase in aerobic metabolism all combine to make cyanide inhibition of the terminal step of electron 
transport (ATSDR 1997) the key molecular target in cyanide poisoning. 
C.4 Health Guidelines 
ATSDR (1997) did not derive inhalation MRLs for cyanide for any exposure duration, because available 
studies were not adequate. Many of the animal and human studies used lethality, or serious effects, as the 
endpoint. Two available epidemiology studies were not used because of inadequate exposure 
characterization or co-exposure to other chemicals. 
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ATSDR (1997) did not derive an acute oral MRLs for cyanide because most of the available studies 
reported lethality as the endpoint, and because of a general lack of information as to acute systemic 
effects of cyanide. 
ATSDR (1997) derived an intermediate oral MRL of 0.05 mg/kg/day for cyanide based on a NOAEL of 
4.5 mg/kg/day for reproductive effects, such as decreased epididymal weight, decreased testis weight, and 
alterations in spermatozoa in male rats (NTP 1993).  The MRL was derived by applying an uncertainty 
factor of 100 (10 for extrapolation from animals to humans and 10 for intrahuman variability) to the 
NOAEL. The rats were exposed for 13 weeks to sodium cyanide in the drinking water. 
ATSDR (1997) has not derived a chronic oral MRL for cyanide, due to limitations of exposure analysis in 
the available human data and a lack of reported effects in the one reported chronic animal study. 
EPA oral RfDs have been established for cyanide and its compounds.  These RfDs range from 
2x10-l mg/kg/day for potassium cyanide to 5x10-3 mg/kg/day for copper cyanide (IRIS 2002). The RfDs 
for potassium silver cyanide and potassium cyanide were based on weight loss and thyroid effects in 
several rat studies (Howard and Hanzel 1955; Philbrick et al. 1979), while the RfD for copper cyanide 
was based on decreased body and organ weights and liver and kidney effects in a intermediate-duration 
rat study (Gerhart 1986).  An EPA RfC exists only for hydrogen cyanide; this RfC is 3x10-3 mg/m3. The 
RfC was based on central nervous system and thyroid effects in a human occupational study (El Ghawabi 
et al. 1975). 
The EPA has determined that cyanide is not classifiable as to its human carcinogenicity (Group D) (IRIS 
2002). No cancer classifications exist for the NTP, Integrated Risk Information System (IRIS), or the 
International Agency for Research on Cancer (IARC) (no available data). 
C.5 Derivation of Target-Organ Toxicity Dose (TTD) Values 
TTDs for chronic oral exposure to cyanide were derived for endpoints affected by one or more of the 
other chemicals in the uranium, fluoride, cyanide, and nitrate mixture that is the subject of this Interaction 
Profile. The relevant endpoints for this mixture include renal, neurological, and reproductive (testicular) 
effects. Where data are available, chronic oral TTDs for these endpoints are derived below, using the 




ATSDR (1997) derived an intermediate oral MRL of 0.05 mg/kg/day for cyanide based on a NOAEL of 
4.5 mg/kg/day for reproductive effects, such as decreased epididymal weight, decreased testis weight, and 
alterations in spermatozoa in male rats (NTP 1993).  The MRL was derived by applying an uncertainty 
factor of 100 (10 for extrapolation from animals to humans and 10 for intrahuman variability) to the 
NOAEL. The rats were exposed for 13 weeks to sodium cyanide in the drinking water. 
Neurological Effects 
While a number of human and animal studies have reported neurologic effects from the ingestion of 
cyanide-containing compounds, none has done so in such a way as to allow for a definitive dose-response 
analysis of the effect of cyanide on neurological endpoints.  For example, Gerhart (1987a, 1987b) 
examined the effects of copper cyanide and potassium silver cyanide in rats, but was not able to clearly 
delineate the effects of cyanide from the effects of the metals.  Similarly, a number of studies in humans 
who consumed cassava, which contains considerable levels of cyanide, are complicated by the presence 
of scopoletin, which may have contributed to the neurological effects seen.  As such, none of the 
available studies are suitable for derivation of a TTD for neurologic effects of cyanide.  The MRL of 
0.05 mg/kg/day will be adopted as the TTDNEURO for cyanide. 
Renal Effects 
Available studies in humans and animals have suggested that renal effects may result from prolonged 
exposure to cyanide, though reliable quantitative data are limited.  The study of Gerhart (1987b), while 
having the limitation of co-exposure to silver, identified a NOAEL of 2.6 mg/kg/day and a LOAEL of 
7.8 mg/kg/day for increased blood urea nitrogen.  Studies in dogs have identified lower LOAEL values, 
but dogs are a poor model for cyanide toxicity in humans due to a lack of rhodanese enzyme levels. 
Application of an uncertainty factor of 100 (10 for animal to human extrapolation and 10 for intrahuman 
variability) would yield a TTDRENAL of 3x10-2 mg/kg/day.  However, as this would fall below the MRL, 
the MRL of 0.05 mg/kg/day will be adopted as the TTDRENAL for cyanide. 
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Summary (TTDs for Cyanide) 
MRLREPRO = 0.05 mg/kg/day 
TTDNEURO = 0.05 mg/kg/day 
TTDRENAL = 0.05 mg/kg/day 
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Appendix D. Background Information for Nitrate 
D.1 Toxicokinetics 
Available studies indicate that oral absorption of nitrate is nearly 100% (for reviews, see EPA 1990 and 
WHO 1978). Witter (1979, cited in EPA 1990) administered oral radioactive nitrate ion to two male 
volunteers; one received the nitrate 1 hour after a large meal, the other about 10 hours after eating.  In the 
subject who had recently eaten, the radioactivity had a disappearance half-life from the stomach of about 
30 minutes, but the radioactivity in the pylorus remained constant, suggesting that the nitrate had moved 
to the small intestine rather than being absorbed through the stomach.  In the second subject, the 
disappearance half-life was 10 minutes.  Studies in animals have also demonstrated that the bulk of an 
orally-administered nitrate exposure is absorbed through the small intestine, likely through the upper 
portion of that organ. Absorbed nitrate is distributed throughout the body, but does not appear to 
accumulate in any organ (EPA 1990). 
The major metabolic pathway for nitrate is conversion to nitrite, and then to ammonia.  Small amounts of 
nitrate, perhaps 5–10% of the total exposure, are converted to nitrite by bacteria in the saliva, stomach, 
and small intestine.  This reaction is pH dependent, with no nitrate reduction occurring below pH 4 and 
above pH 9, and the presence of oxygen inhibits the reduction of nitrite to ammonia.  Absorbed nitrite 
rapidly reacts with hemoglobin in the blood to form methemoglobin, which in adults, is rapidly converted 
to oxyhemoglobin, then back to hemoglobin.  In infants, particularly those under 3 months old, these 
reducing systems are not fully developed, which may result in a buildup of methemoglobin in the blood. 
Due to the higher stomach pH typically found in infants, it is believed that they also convert more nitrate 
to nitrite in the stomach than adults.  There are large species differences in the rate of reaction of nitrite 
with hemoglobin, paralleled by similar differences in the rates of reduction of methemoglobin, making 
extrapolation of results from animal data to humans problematic.  Another potential metabolic pathway, 
though less prevalent than the reaction with hemoglobin, is the reaction of nitrite with endogenous 
molecules to form N-nitroso compounds, many of which have toxic effects, including carcinogenicity. 
Available data in humans have demonstrated that elimination of ingested nitrate is rapid, with elimination 
almost exclusively in the urine (EPA 1990; WHO 1978).  Animal data support this observation.  In both 
humans and animals, considerably more nitrate is eliminated in the urine than is ingested in a normal diet, 
implying that there is significant endogenous nitrate formation. 
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Parks et al. (1981, cited in EPA 1990) reported that following intratracheal instillation of trace amounts of 
nitrate to BALB/C mice, absorption from the lungs was complete within a 10-minute period.  Additional 
studies of the toxicokinetics of inhaled nitrate are not available; however, the behavior of absorbed nitrate 
following inhalation exposure is not expected to differ from nitrate absorbed following oral exposure. 
D.2 Health Effects 
The most sensitive known effects of exposure to nitrate result from increased levels of methemoglobin 
arising from the nitrite-hemoglobin reaction.  In healthy adults, methemoglobin formation and reduction 
is continuous, with steady-state methemoglobin levels in healthy adults being 2.5% of the total 
hemoglobin content or lower (EPA 1990).  Due to the large excess capacity of the blood to carry oxygen, 
levels of methemoglobin up to 10% typically do not cause significant clinical signs.  Levels above 
10% may result in cyanosis, weakness, rapid pulse, and, at levels exceeding 50%, death.  Other reported 
effects of nitrate in animals include altered thyroid function, amyloidosis of the liver, kidney, spleen, and 
adrenal glands, and altered lung and liver weights. 
Because of greater numbers of nitrate-reducing bacteria in the gastrointestinal tract and diminished 
methemoglobin-reducing capacity, infants, particularly those 3 months and younger, are particularly 
susceptible to nitrate/nitrite-induced methemoglobinemia.  A study by Bosch et al. (1950) examined 
139 cases of methemoglobinemia in young children (90% occurred in children <2 months of age). 
Examination of the wells used to supply water to the children revealed that none of the wells supplied 
<10 mg/L nitrate-nitrogen, with all but two of the wells containing >25 mg/L.  Walton (1951) presented 
the results of a survey on morbidity and mortality among infants due to methemoglobinemia.  The results 
of the survey revealed 239 cases of infant methemoglobinemia, 39 of them fatal.  Of the 214 cases where 
quantitative data were available on nitrate levels in water, none occurred in infants consuming water with 
<10 mg/L nitrate-nitrogen, 5 cases occurred in infants exposed to 11–20 mg/L nitrate-nitrogen, 36 cases 
in infants exposed to 21–50 mg/L nitrate-nitrogen, and 173 cases in infants exposed to >50 mg/L nitrate-
nitrogen. Many other studies have examined the effects of high (>20 mg/L) levels of nitrate in the 
drinking water of infants, and have found increased methemoglobin levels and signs of clinical 
methemoglobinemia in exposed infants (for reviews, see EPA 1990 and WHO 1978). 
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D.3 Mechanisms of Action 
The known toxic effects of nitrate exposure result from the conversion of nitrate to nitrite.  The 
conversion is mainly the result of bacterial oxidation reactions within the gastrointestinal tract.  Exposure 
of hemoglobin to nitrite results in the oxidation of the Fe2+ ion in the heme of hemoglobin to Fe3+, 
resulting in the formation of methemoglobin.  Methemoglobinemia results in the majority of the 
symptoms seen following high-dose acute nitrate exposure in humans.  Under normal conditions, healthy 
adults will have <2.5% methemoglobin in the blood.  Methemoglobin can be reduced back to hemoglobin 
by both spontaneous (nicotinamide adenine dinucleotide phosphate [NADH]-dependent) and dormant 
(NADPH-dependent) methemoglobin reductase enzymes. 
Infants are particularly susceptible to methemoglobinemia due to their high gut content of nitrate-
reducing bacteria, their lower enzymatic capacity to reduce methemoglobin to hemoglobin, and to the 
presence of hemoglobin F, which is more susceptible to oxidation by nitrite.  The high pH of the infant 
gastrointestinal system favors the growth of nitrate-reducing bacteria, particularly in the stomach and 
especially after ingestion of contaminated waters, since the ingested bacteria are likely to flourish in the 
stomach.  The stomach of adults is typically too acidic to allow for significant bacterial growth and the 
resulting conversion of nitrate to nitrite. Additionally, the enzymes involved in the conversion of 
methemoglobin to hemoglobin do not fully develop in humans until between 3 and 6 months after birth, 
resulting in an increased susceptibility to methemoglobinemia. 
As mentioned in Section D.1, the reaction rates for the nitrite-hemoglobin reaction vary considerably 
across species (many animal species lack nitrate-reducing bacteria), as do the rates of the reactions 
reducing methemoglobin back to functional hemoglobin. Also, since the rates of conversion of nitrate to 
nitrite by bacteria can vary within individuals, the extent of nitrate toxicity can also vary greatly 
depending on age and other factors within both humans and animals. 
D.4 Health Guidelines 
ATSDR has not published a toxicological profile for nitrates. No MRL values are available. 
EPA (IRIS 2002) has derived an oral RfD of 1.6 mg/kg/day for nitrate, based on a NOAEL of 
1.6 mg/kg/day for methemoglobinemia in exposed infants (Bosch et al. 1950; Walton 1951).  An 
uncertainty factor of 1 was applied to the NOAEL since the study was performed in a sensitive population 
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of humans (infants age 0–3 months).  No RfC for nitrate has been derived, and nitrate has not undergone 
an evaluation of carcinogenic potential by EPA. 
D.5 Derivation of Target-Organ Toxicity Dose (TTD) Values 
ATSDR has not published a toxicological profile for nitrates; no MRLs exist for exposure to nitrate by 
any route of exposure.  As no shared targets of toxicity for nitrate and any of the other components of the 
mixture exist, no TTDs for nitrate were derived. 
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